Document:

exv10w40

 

Exhibit 10.40

[..**..] = Certain
 Confidential Information Contained

in this Document, Marked by Brackets, Has Been

Omitted and Filed Separately with the Securities

and Exchange Commission Pursuant to rule 24b-2

of the Securities Exchange Act of 1934, as Amended.

Exhibit A-1

LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

     This License, Development and Commercialization Agreement (this “Agreement”) is made
this                      day of                     , 200___ by and between Myogen, Inc. (“Myogen”), a Delaware
corporation with principal offices at 7575 West 103rd Avenue, Westminster, Colorado
80021, and Novartis Institutes for BioMedical Research, Inc. (“NIBRI”), a Delaware
corporation with principal offices at 400 Technology Square, Cambridge, Massachusetts 02139.

     Capitalized terms used but not defined in this Agreement have the meanings provided in the
Collaboration and Option Agreement by and between the parties dated as of October 8, 2003, as
amended and restated on July 7, 2006 (the “Collaboration Agreement”).

Introduction

     WHEREAS, pursuant to the Collaboration Agreement, Myogen and NIBRI are, or have been,
engaged in discovering and developing compounds having a specific therapeutic effect on the Myogen
Targets or Collaboration Targets (each as defined in the Collaboration Agreement);

     WHEREAS, NIBRI has exercised its Option under the Collaboration Agreement to license
exclusively one or more of the Development Candidates (as defined herein) for development and
commercialization in the Licensed Field (as defined herein) and in the Territory;

     NOW THEREFORE, in consideration of the foregoing premises, the parties agree as follows:

[..**..] Confidential Treatment Requested

1

 

ARTICLE I

Definitions

     1.1. “Active Compound” shall have the meaning set forth in the Collaboration Agreement.

     1.2. “Affiliate” shall have the meaning set forth in the Collaboration Agreement.

     1.3. “Cardiac Field” shall mean the research, treatment, prognosis, diagnosis, prophylaxis,
and monitoring of heart muscle disease.

     1.4. “Collaboration Agreement” shall mean that certain Collaboration and Option Agreement
dated as of October 8, 2003, as amended and restated on July 7, 2006, by and between Myogen and
NIBRI, and as amended or restated by Myogen and NIBRI from time-to-time thereafter.

     1.5. “Collaboration Compound” shall have the meaning set forth in the Collaboration Agreement.

     1.6. “Collaboration Target” shall have the meaning set forth in the Collaboration Agreement.

     1.7. “Commencement Date” shall mean, with respect to the application of this Agreement to a
Development Candidate, the date on which NIBRI exercised its Option under Section 4.4 of the
Collaboration Agreement with respect to that Development Candidate.

     1.8. “Compound” shall have the meaning set forth in the Collaboration Agreement.

     1.9. “Controlled” shall have the meaning set forth in the Collaboration Agreement.

     1.10. “Co-Promotion Expenses” shall mean, with respect to each Drug Product, out-of-pocket
costs and other costs (in the case of personnel costs for personnel directly involved in the
marketing or promotional activities, excluding sales personnel and field service supervisors) which
are incurred by a party or any of its Affiliates solely in connection with marketing or promotional
activities in the Cardiac Field or Expanded Cardiovascular Field, as the case may be, including,
without limitation, costs in the following categories (in each case to the extent

[..**..] Confidential Treatment Requested

2

 

incurred in connection with activities in the Cardiac Field or the Expanded Cardiovascular
Field, as the case may be):

     (a) costs incurred in promoting and marketing such Drug Product, including without
limitation, advertising (including agency fees), market research, patient-oriented
promotions, meetings, pre-launch activities and expenses relating to launch of the Drug
Product, and managed markets/health authority liaisons (but excluding detailing expenses);

     (b) amounts repaid or credited for bad debts;

     (c) costs associated with post-marketing drug safety surveillance;

     (d) medical affairs costs, and costs associated with medical/scientific liaisons
(including regional scientific directors), medical education and publications, professional
symposia, advisory boards, speaker and activity programs;

     (e) costs of Phase IV Clinical Trials in the Territory and pharmacoeconomic studies;

     (f) the cost of samples;

     (g) costs of materials and programs for the training of sales force and marketing
management;

     (h) costs of promotional materials, telemarketing, e-marketing, field and headquarters’
grants, exhibits, direct mail and sample alternative programs;

     (i) all costs associated with the maintenance of Regulatory Approvals;

     (j) costs associated with any sales force training agreed to by NIBRI;
provided, however, that each party will train its own sales force (and that
of its Affiliates) at its own expense;

     (k) amounts paid to a Third Party in order to obtain freedom to operate with respect to
such Drug Product in the Territory; and

[..**..] Confidential Treatment Requested

3

 

     (l) amounts paid, whether in damages or by a settlement approved by NIBRI, to a Third
Party in the Territory as a result of any allegation of infringement by any party of a Third
Party patent by the manufacture, development or commercialization of such Drug Product.

     The foregoing shall not include any costs which: (i) are incurred prior to the Commencement
Date; (ii) are incurred in connection with the manufacture of any Drug Product; or (iii) have been
included in Development Costs or Regulatory Expenses.

     1.11. “Co-Promotion Notice” shall have the meaning set forth in Section 3.5(a) hereof.

     1.12. “Co-Promotion Response” shall have the meaning set forth in Section 3.5(a) hereof.

     1.13. “Co-Promotion Share” shall have the meaning set forth in Section 3.5(a) hereof.

     1.14. “Development Candidate” shall mean the NIBRI Compound, Myogen Compound or the
Collaboration Compound, together with the Myogen Target or Collaboration Target on which it has
therapeutic action, as to which NIBRI exercised its Option under the Collaboration Agreement and
entered into this Agreement, and any derivatives thereof whether or not they were developed before
or after the execution of this Agreement.

     1.15. “Development Costs” shall mean, with respect to a Development Candidate and Drug
Products derived therefrom, expenses and other costs, including Regulatory Expenses (except for the
maintenance of Regulatory Approvals), incurred by or on behalf of a party in connection with the
worldwide development of such Development Candidate and Drug Products derived therefrom in
accordance with the Development Program in the Cardiac Field or the Expanded Cardiovascular Field,
as the case may be, including without limitation the costs of clinical trials, the preparation,
collation and/or validation of data from such clinical trials and the preparation of medical
writing as will make the results of such clinical trials an element of one or more Registration
Filings in the Cardiac Field or Expanded Cardiovascular Field, as applicable; provided,
that Development Costs shall include: (a) the cost of any preclinical or clinical studies
conducted by NIBRI or its Affiliates in connection with a Development Program outside the

[..**..] Confidential Treatment Requested

4

 

Cardiac Field or Expanded Cardiovascular Field, as applicable (and not reimbursed or paid by a
Third Party), to the extent the results of such studies are required to be performed under
applicable regulatory guidelines specific to the indication being studied in the Cardiac Field or
Expanded Cardiovascular Field, as applicable, and incorporated as part of any Registration Filings
submitted to support a Regulatory Approval for an indication in the Cardiac Field or Expanded
Cardiovascular Field, as applicable; and (b) the cost of Phase IIIB clinical trials and Phase IV
clinical trials only if and to the extent they are intended to support indications in the Cardiac
Field or Expanded Cardiovascular Field, as applicable, beyond the respective initial indications
(as agreed upon by the parties) for the Drug Products, to support expanded labeling for the Drug
Products, or to satisfy requirements imposed by governmental regulatory authorities in connection
with Regulatory Approvals for the Products in the Cardiac Field or the Expanded Cardiovascular
Field, as applicable. Development Costs consist of:

     (a) all out-of-pocket costs incurred by the parties or their Affiliates, including
payments made to Third Parties with respect to any of the foregoing;

     (b) the fully allocated costs of internal scientific or technical personnel engaged in
such efforts, which costs shall be determined based on the FTE annual rate or such other
basis as may otherwise be agreed by the parties;

     (c) the costs of clinical supplies for such efforts as agreed in the applicable
approved Development Program in the Cardiac Field or the Expanded Cardiovascular Field, as
applicable, including: (i) the fully allocated cost or out-of-pocket costs, as applicable,
incurred in purchasing and/or packaging comparator drugs; and (ii) disposal of clinical
samples;

     (d) the costs and expenses incurred in connection with technical development and with
other manufacturing development activities; and

     (e) any other costs or expenses explicitly included in the Development Program in the
Cardiac Field or the Expanded Cardiovascular Field, as the case may be.

     1.16. “Development Program” shall mean activities associated with development of Active
Compounds as Development Candidates for sale as Drug Products in the Cardiac Field or

[..**..] Confidential Treatment Requested

5

 

the Expanded Cardiovascular Field, as the case may be, in the Territory, including but not
limited to: (a) formulation of Active Compounds as Development Candidates for use in preparation
for preclinical studies; (b) preclinical animal studies performed in accordance with GLP (or the
applicable equivalent) in preparation for the filing of an IND (or the applicable equivalent); (c)
formulation and manufacture of Active Compounds as Development Candidates for preclinical and
clinical studies; (d) planning, implementation, evaluation and administration of human clinical
trials; (e) manufacturing process development and scale-up for the manufacture of bulk Active
Compound and Drug Product; (f) preparation and submission of applications for regulatory approval;
and (g) post-market surveillance of approved drug indications, as required or agreed as part of a
marketing approval by any governmental regulatory authority.

     1.17. “Drug Product” shall mean a product prepared from bulk Active Compound with respect to a
Development Candidate, in finished dosage form ready for administration to the ultimate consumer as
a pharmaceutical.

     1.18. “European Co-Promotion Share” shall be equal to: (a) [..**..] of the
Co-Promotion Share for the first year following the commercial launch of the Drug Product in any of
the European Countries; (b) [..**..] of the Co-Promotion Share for the second year
following the commercial launch of the Drug Product in any of the European Countries; and (c)
[..**..] of the Co-Promotion Share for the third and each successive year following the
commercial launch of the Drug Product in any of the European Countries.

     1.19. “European Countries” shall mean the United Kingdom, Germany, France, Italy and Spain.

     1.20. “Expanded Cardiovascular Field” shall mean the research, treatment, prognosis,
diagnosis, prophylaxis, and monitoring of cardiovascular disease, cardio-renal disease and
cardio-pulmonary disease.

     1.21. “Expiration Date” shall have the meaning set forth in Section 8.1 hereof.

[..**..] Confidential Treatment Requested

6

 

     1.22. “First Commercial Sale” shall mean the first shipment of a Drug Product to a Third Party
by NIBRI or an Affiliate or sublicensee of NIBRI in a country in the Territory following applicable
Regulatory Approval of the Drug Product in such country.

     1.23. “GCP” shall mean the current Good Clinical Practice standards for clinical trials for
pharmaceuticals, as set forth in the Food, Drug and Cosmetic Act and applicable regulations
promulgated thereunder, as amended from time to time, and such standards of good clinical practice
as are required by the regulatory authorities of the organizations and governmental agencies in
countries in which Drug Products are intended to be sold.

     1.24. “GLP” shall mean the current Good Laboratory Practices regulations promulgated by the
FDA, published at 21 CFR Part 58, as such regulations may be from time to time amended, and such
equivalent regulations or standards of countries outside the United States as may be applicable to
activities conducted hereunder.

     1.25. “GMP” shall mean the current Good Manufacturing Practice regulations promulgated by the
FDA, published at 21 CFR Part 210 et seq., as such regulations may be amended, and such equivalent
foreign regulations or standards as may be applicable with respect to bulk Active Compound or a
Drug Product manufactured or sold outside the United States.

     1.26. “Gross Contribution” means, with respect to Drug Products co-promoted by the parties in
accordance with Section 3.5 hereof, [..**..], in the United States and/or the European
Countries (as applicable), less the following:

	 	(a)	 	[..**..]; and
	 
	 	(b)	 	[..**..].

     1.27. “Improvement” means any enhancement in the formulation, ingredients, preparation,
presentation, means of delivery, dosage, packaging of, manufacture, or any new or expanded
therapeutic indication(s) for, an Active Compound, a Drug Product, or any other metabolite or
isomer thereof.

     1.28. “Improvement Patent” means any Patent (except for the formulation Patent and use Patent
with respect to a Development Candidate) containing claims that cover an Improvement.

[..**..] Confidential Treatment Requested

7

 

     1.29. “IND” shall mean an application to the Food and Drug Administration, the filing of which
is necessary to commence clinical testing of Compounds in humans, or the equivalent application to
the equivalent agency in any other country or group of countries.

     1.30. “In Vivo Validation” means, with respect to an Active Compound, the achievement of
physiologically significant activity in an appropriate in vivo model or models, where the level of
physiologically significance and the in vivo model(s) to be used will be specified by the JSC with
respect to High Priority Targets and Low Priority Targets and by Myogen with respect to
Extra-Collaboration Targets.

     1.31. “Joint Patent” shall mean a Patent which, absent rights thereunder, would be infringed
by the research, development, manufacture, use, importation, sale, or distribution of the
Development Candidate or a Drug Product relating thereto, and is owned or Controlled jointly by
NIBRI or a NIBRI Affiliate, on the one hand, and Myogen or a Myogen Affiliate, on the other hand.

     1.32. “Joint Know-How” shall mean Know-How that is owned or Controlled jointly by NIBRI or a
NIBRI Affiliate, on the one hand, and Myogen or a Myogen Affiliate, on the other hand.

     1.33. “Joint Technology” shall mean Joint Patents and Joint Know-How.

     1.34. “Know-How” means all Technology other than inventions that are the subject of Patents,
including, but not limited to, information, technical information, techniques, data, inventions,
discoveries, trade secrets, processes, practices, methods, materials, compositions, formulas,
improvements, knowledge, know-how, skill, experience, or test data, whether or not patented or
confidential, which is Controlled by a party relating to the Myogen Technology or the development,
manufacture, use, sale, offer for sale, or import of any Active Compound, Development Candidate, or
Drug Product, or any Improvement thereto, including (but not limited to), pharmacological,
toxicological, pre-clinical and clinical test data, analytical and quality control data, packaging,
marketing, pricing, distribution, sales and manufacturing data or descriptions,
compositions-of-matter, assays and biological materials related thereto and the content of this
Agreement.

[..**..] Confidential Treatment Requested

8

 

     1.35. “Know-How Period” shall have the meaning set forth in Section 8.1.

     1.36. “Licensed Field” shall mean all human and veterinary health care applications including,
but not limited to, research, prognosis and diagnosis (subject to Section 2.5), therapeutics,
prophylaxis, and monitoring with respect to any indication, together with all agricultural
purposes.

     1.37. “Licensed Patents” shall mean any Myogen Patents that become the subject of NIBRI’s
rights under Article II of this Agreement upon exercise of its license and development option in
accordance with the provisions of Section 4.4 of the Collaboration Agreement.

     1.38. “Listed Country” shall mean a country listed on Schedule 1.38 hereof, as Schedule 1.38
may be amended from time to time on mutual written agreement of the parties.

     1.39. “Live Claim” shall mean a claim of any issued, unexpired Licensed Patent that shall not
have been withdrawn, canceled or disclaimed, nor held invalid or unenforceable by a court of
competent jurisdiction in an unappealed or unappealable decision.

     1.40. “Myogen Compound” shall have the meaning set forth in the Collaboration Agreement.

     1.41. “Myogen Know-How” shall have the meaning set forth in the Collaboration Agreement, as
the same shall exist on the Commencement Date and at any time during the term of this Agreement.

     1.42. “Myogen Patents” shall have the meaning set forth in the Collaboration Agreement, as in
effect on the Commencement Date and at any time during the term of this Agreement. A list of
Myogen Patents is appended hereto as Schedule 1.42 and will be updated periodically to reflect
additions thereto during the course of this Agreement.

     1.43. “Myogen Target” shall have the meaning set forth in the Collaboration Agreement.

     1.44. “Myogen Technology” shall mean all Myogen Patents and Myogen Know-How.

     1.45. “NDA” means a New Drug Application submitted to the Food and Drug Administration seeking
approval to market and sell a Drug Product in the Licensed Field in the

[..**..] Confidential Treatment Requested

9

 

United States of America, or a corresponding application filed with any other regulatory
agency seeking approval to market and sell a Drug Product in the Licensed Field in a country in the
Territory.

     1.46. “Net Sales” shall mean, with respect to a Drug Product, the gross amount invoiced by
NIBRI and any NIBRI Affiliate, sublicensee or marketing partner to Third Party customers for the
Drug Product, less:

     (a) Normal and customary trade and quantity discounts and non-affiliated brokers’ or
agents’ commissions actually allowed and taken and not already reflected in the amount
invoiced;

     (b) Amounts repaid or credited by reason of defects, rejections, returns, recalls,
allowances, or retroactive price reductions;

     (c) Third Party cash rebates and chargebacks related to sales of finished Drug
Products, to the extent allowed;

     (d) Retroactive price reductions that are actually allowed or granted;

     (e) Tariffs, duties, excise, sales, value-added, and other consumption taxes and
customs duties to the extent included in the invoice price and paid by or on behalf of
NIBRI;

     (f) Cash discounts for timely payment;

     (g) Delayed ship order credits;

     (h) Discounts pursuant to indigent patient programs and patient discount programs of
any nature;

     (i) A fixed charge of [..**..] to cover warehousing and distribution expenses;
and

     (j) Any other specifically identifiable costs or charges included in the gross invoiced
sales price of such Drug Product falling within categories substantially equivalent to those
listed above;

[..**..] Confidential Treatment Requested

10

 

provided that:

     (i) In the case of any sale or other disposal of a Drug Product between or
among NIBRI and its Affiliates, sublicensees or marketing partners, for resale, Net
Sales shall be calculated as above only on the value charged or invoiced on the
first arm’s length sale to a Third Party;

     (ii) In the case of any sale or other disposal, such as barter or
counter-trade, of any Drug Product, or part thereof, otherwise than in an arm’s
length transaction exclusively for money, Net Sales shall be calculated as above on
the value of the consideration received or, if higher, on the fair market price of
the Drug Product in the relevant country of sale or disposal; and

     (iii) In the event that a Drug Product is sold as part of a combination
product, Net Sales of the Drug Product, for the purpose of determining royalty
payments, shall be determined by multiplying Net Sales (as defined above) of the
combination product by the fraction A/(A+B), where A is the weighted (by sales
volume) average sales price of the Drug Product when sold separately in finished
form and B is the weighted average sale price of the other product(s) sold
separately in finished form. In the event that such average sales price cannot be
determined for both the Drug Product and the other product(s) in combination, Net
Sales for purposes of determining payments hereunder shall be mutually agreed by the
parties based on the relative value contributed by each component, and such
agreement shall not be unreasonably withheld.

     1.47. “NIBRI Compound” shall have the meaning set forth in the Collaboration Agreement.

     1.48. “NIBRI Know-How” shall have the meaning set forth in the Collaboration Agreement, as the
same shall exist on the Commencement Date and at any time during the term of this Agreement with
respect to the Development Candidate, any Drug Product incorporating the same, and their respective
use and manufacture.

[..**..] Confidential Treatment Requested

11

 

     1.49. “NIBRI Patents” shall have the meaning set forth in the Collaboration Agreement, as in
effect on the Commencement Date and at any time during the term of this Agreement.

     1.50. “NIBRI Technology” shall mean all NIBRI Patents and NIBRI Know-How.

     1.51. “Patent Period” shall have the meaning set forth in Section 8.1.

     1.52. “Patents” shall mean all existing patents and patent applications and all patent
applications hereafter filed, including any continuation, continuation-in-part, division,
provisional or any substitute applications, any patent issued with respect to any such patent
applications, any reissue, reexamination, renewal or extension (including any supplementary
protection certificate) of any such patent, and any confirmation patent or registration patent or
patent of addition based on any such patent, and all foreign counterparts of any of the foregoing.

     1.53. “Person” shall mean any individual, corporation, partnership, association, limited
liability company, trust, unincorporated organization or government or political subdivision
thereof.

     1.54. “Phase I Clinical Trial” shall mean a clinical study, conducted in accordance with a
protocol approved by NIBRI of a Drug Product in human volunteers with the endpoint of determining
initial tolerance, safety and/or pharmacokinetic information in single dose, single ascending dose,
multiple dose and/or multiple ascending dose regimens.

     1.55. “Phase II Clinical Trial” shall mean a clinical study, conducted in accordance with a
protocol approved by NIBRI, of a Drug Product in patients to determine initial efficacy and dose
range finding.

     1.56. “Phase III Clinical Trial” shall mean a clinical study in patients, conducted in
accordance with a protocol approved by NIBRI, which protocol is designed to ascertain efficacy and
safety of a Drug Product for the purpose of preparing and submitting a filing for Regulatory
Approval in a particular country in the Territory.

     1.57. “Phase IV Clinical Trial” shall mean a clinical study initiated in a country after
receipt of Regulatory Approval for a Drug Product in such country.

[..**..] Confidential Treatment Requested

12

 

     1.58. “Registration Filing” shall mean, with respect to each Development Candidate or related
Drug Product, the submission to the relevant governmental regulatory authority of an appropriate
application seeking any Regulatory Approval, and shall include, without limitation, any marketing
authorization application, supplementary application or variation thereof, or any equivalent
applications.

     1.59. “Regulatory Approval” shall mean, with respect to a country in the Territory, all
authorizations by the appropriate governmental entity or entities necessary for commercial sale of
a Drug Product in that country including, without limitation and where applicable, approval of
labeling, price, reimbursement and manufacturing.

     1.60. “Regulatory Expenses” shall mean, with respect to a Development Candidate or related
Drug Product, all out-of-pocket costs and fully allocated costs incurred by or on behalf of a party
in connection with the preparation and filing of Registration Filings and the maintenance of
Regulatory Approvals.

     1.61. “Technology” shall mean all data, technical information, know-how, experience,
inventions (whether or not patented), trade secrets, processes and methods discovered, developed or
applied (with the consent of its owner) and Controlled by either party or its Affiliates, in
connection with performance by either party under the Research Program, or in connection with the
conduct of a Development Program, that relate to the research, development, utilization,
manufacture or use of Targets or Compounds.

     1.62. “Territory” shall mean [..**..].

     1.63. “Third Party” shall mean any Person that is not a party or an Affiliate of any party to
this Agreement.

ARTICLE II

Rights and Licenses

     2.1. NIBRI Rights. Subject to the other provisions of this Agreement, Myogen grants to
NIBRI and its Affiliates a license, exclusive even as to Myogen, with the right to sublicense,
under the Myogen Patents and the Myogen Know-How and in the Licensed Field, to research

[..**..] Confidential Treatment Requested

13

 

and have researched, develop and have developed, make and have made, and use and have used the
Development Candidate and to research and have researched, develop and have developed, make and
have made, manufacture and have manufactured, use and have used, market and have marketed,
distribute and have distributed, sell and have sold, export and import for sale, and have exported
or imported for sale, Drug Products in each country in the Territory. NIBRI understands that the
licenses granted under this Agreement to certain Myogen Technology that has been licensed by Myogen
pursuant to agreements with the University of Texas Southwestern Medical Center, the University of
North Texas Health Sciences Center and the University Licensing and Equity Holdings, Inc. are
subject to the retained rights of such licensors to use such Myogen Technology for research,
teaching and other educationally-related, non-commercial purposes. Myogen retains all rights to
Myogen Technology except to the extent explicitly granted to NIBRI hereunder.

2.2. Scope of Exclusivity; Diligence; Development Responsibility.

     (a) As long as NIBRI is using commercially reasonable efforts to diligently develop
and/or commercialize the Development Candidate in the Licensed Field:

     (i) The licenses granted to NIBRI in Section 2.1 shall be effective also with
respect to any other Active Compound which falls under the same Live Claim as an
Active Compound constituting the Development Candidate provided that all of the
terms and conditions of this Agreement (including royalty and milestone payments)
shall apply to all such other Active Compounds; and

     (ii) Myogen shall not develop, make, have made, use, market and sell, itself or
through a Third Party licensee, for use within the Licensed Field, any other Active
Compound which falls under the same Live Claim as an Active Compound constituting
the Development Candidate.

     (b) NIBRI shall be deemed to be using commercially reasonable efforts with respect to
the provisions of Section 2.1 and Section 3.4 if NIBRI or any of its Affiliates is actively
undertaking diligent, commercially reasonable efforts, similar to those used for other
products of NIBRI or its Affiliates that are of similar commercial potential, for the
continuing development and the commercialization of the Development Candidate in the

[..**..] Confidential
 Treatment Requested

14

 

Licensed Field, including, without limitation, the development and/or optimization
and/or further characterization of Active Compounds, initiation and conduct of clinical
trials, submission of regulatory filings and commercial launch of Drug Products.

     (c) Except as otherwise provided herein, NIBRI will have sole responsibility for, and
bear the cost of conducting, the Development Program with respect to each Development
Candidate and/or seeking Regulatory Approval of any Drug Product.

     2.3. Joint Inventions and Joint Patents. All inventions conceived of and reduced to practice
during the term of, or as a result of, this Agreement, jointly by employees or agents of Myogen or
its Affiliates, on one hand, and employees or agents of NIBRI or its Affiliates, on the other hand
(“Joint Inventions”) and all Patent applications and Patents claiming Joint Inventions,
shall be owned jointly by Myogen and NIBRI, and such Patent applications and Patents shall be
included within the Joint Patents. The rights of each party with respect to the Joint Technology
shall be determined in accordance with United States patent law as it applies to issues of joint
ownership of intellectual property as of the Effective Date of the Collaboration Agreement.

     2.4. Inventions Necessary to the License. If Myogen conceives and reduces to practice during
the term of this Agreement any new Technology relating to a Development Candidate or Drug Product
and covered by a Myogen Patent, or acquires or Controls (either on the Effective Date or at any
time during the term of this Agreement) any Patent on a Technology, and such Technology is
necessary to NIBRI’s exercise of its licensed rights in the Cardiac Field, then the definition of
Myogen Patent will be deemed to include such Patents that are included within the licenses granted
to NIBRI under this Agreement.

     2.5. Diagnostic and Prognostic Products. In the event that NIBRI desires to develop and
commercialize any diagnostic or prognostic products based upon any Development Candidate, the
parties agree to negotiate in good faith the terms under which NIBRI would be granted rights to
develop and commercialize such products.

     2.6. Right of First Negotiation to Discontinued NIBRI Compounds. In the event that NIBRI
elects to discontinue the Development Program with respect to a NIBRI Compound or elects to
terminate this Agreement for its convenience, and NIBRI subsequently contemplates collaborating
with a Third Party with respect to development and/or commercialization of such

[..**..] Confidential Treatment Requested

15

 

NIBRI Compound, NIBRI shall give Myogen written notice of the same. Within [..**..]
of receipt of such notice, Myogen shall inform NIBRI in writing as to whether it wishes to
negotiate in good faith a license to such NIBRI Compound within the Licensed Field. If Myogen so
informs NIBRI, then the parties shall have [..**..] to negotiate a transaction in good
faith. If the parties are unable to consummate a transaction within such period (or such longer
period as the parties may agree to in writing), then NIBRI may enter into a Third Party transaction
with respect to the NIBRI Compound. All other rights to discontinued Compounds shall be governed
by the terms of the Collaboration Agreement.

ARTICLE III

Development and Commercialization

     3.1. Development and Commercialization Rights. Subject to any co-funding/co-promotion
rights granted to Myogen pursuant to Section 3.5 hereof, NIBRI, its Affiliates and/or sublicensees,
if any, shall have sole rights, even as to Myogen, in the Licensed Field to develop and manufacture
on a commercial scale the Development Candidate, the related Drug Product, and the active
ingredient in such Drug Product in the Territory, and to commercialize, manufacture, promote, sell,
book sales, and distribute each Drug Product and/or the active ingredient in such Drug Product in
each country in the Territory. (The foregoing right to manufacture is subject to any applicable
United States statutory requirement that technology the development of which was funded in part by
the United States government must be manufactured domestically, unless the United States government
shall waive such requirement.) NIBRI and its Affiliates, in their sole discretion, shall select,
file, and own all rights to any and all trademarks and trade dress relating to the Drug Product.

     3.2. Information Transfer. Myogen shall deliver (to the extent not previously delivered to
NIBRI pursuant to the Collaboration Agreement) as promptly as practicable to NIBRI all information
in Myogen’s possession or under its control (including summaries of raw data from clinical studies
conducted by Myogen of each Active Compound and related Myogen Target or Collaboration Target
comprising the Development Candidate), all scientific reports, and all processes and procedures
that are necessary or useful for further development,

[..**..] Confidential Treatment Requested

16

 

manufacture and commercial exploitation and distribution of the Development Candidate in the
Territory. Such information shall include a summary of all material written communications (copies
of which Myogen will provide to NIBRI at NIBRI’s request) between Myogen or (to the extent
available to Myogen) its other licensees and the Food and Drug Administration (or any other similar
regulatory authority) concerning the Development Candidate. This information shall also include
copies of all Patents, copyrights, copyright registrations and applications therefor and all other
manifestations of the intellectual property embodied in the Development Candidate, whether in human
or machine readable form. Information provided by Myogen will be subject to the provisions of
Article VI hereof.

     3.3. Regulatory Approvals. NIBRI and/or its Affiliates will be responsible for all required
Regulatory Approvals in the Territory. All filings will be made by NIBRI and/or its Affiliates.
All Regulatory Approvals will be held in the name of NIBRI and/or its Affiliates. NIBRI and its
Affiliates shall have the right to cross-reference information and regulatory filings relating to
the Development Candidate arising out of development work which previously has been conducted by
Myogen and its Affiliates and licensees, for the purpose of regulatory filings hereunder.

     3.4. Due Diligence. Upon exercise of its Option with respect to a Development Candidate,
NIBRI and its Affiliates shall commence a Development Program with respect to such Development
Candidate and shall use commercially reasonable efforts (as defined in Section 2.2(b)) to effect
introduction of the Drug Product relating to such Development Candidate into one or more commercial
markets in the Territory. In the normal course of development, any Development Candidate may be
dropped from development for valid scientific or medical reasons provided to Myogen by NIBRI in
writing and may be replaced (at the sole discretion of NIBRI and/or its Affiliates) with one or
more other Development Candidates having a therapeutic action on the same Myogen Target or
Collaboration Target, and such occurrence shall not constitute a failure of due diligence.

     3.5. Co-Funding and Co-Promotion Option.

     (a) Following the completion of Phase II Clinical Trials with positive results leading
to NIBRI’s reasonable expectation that it will conduct Phase III Clinical Trials

[..**..] Confidential Treatment Requested

17

 

and generation of relevant reports, NIBRI will provide Myogen with a report containing
all relevant pre-clinical data and all relevant clinical data from the Phase I Clinical
Trials and the Phase II Clinical Trials and a preliminary estimate of anticipated
Co-Promotion Expenses (including sales force details) (the “Co-Promotion Notice”).
In the event that Myogen wishes to co-fund and co-promote such Development Candidate in the
Cardiac Field or, solely to the extent that NIBRI or its Affiliates are no longer pursing a
Development Program with respect to such Development Candidate that was developed from a
Myogen Compound in the Cardiac Field but are pursuing a Development Program with respect to
such Development Candidate in the Expanded Cardiovascular Field, in the Expanded
Cardiovascular Field, either the United States, or the United States and the European
Countries, Myogen shall give NIBRI written notice of the same no later than
[..**..] after its receipt of the Co-Promotion Notice (the “Co-Promotion
Response”). The Co-Promotion Response will specify the level of financial commitment
that Myogen will assume with respect to the co-funding of such Development Candidate and the
co-promotion of such Development Candidate in the United States in the Cardiac Field or the
Expanded Cardiovascular Field, as the case may be (the “Co-Promotion Share”) and
whether Myogen wishes to co-fund and co-promote such Development Candidate in the European
Countries; provided, that Myogen shall be required to commit to fund no less than
[..**..] and no greater than [..**..] of the Development Costs and
Co-Promotion Expenses of such Development Candidate that are attributable to the development
of the Development Candidate in the Cardiac Field or the Expanded Cardiovascular Field, as
the case may be, in the United States and, if applicable, the European Countries.

     (b) Along with the Co-Promotion Response, Myogen will provide NIBRI with certification
to NIBRI’s reasonable satisfaction that it has the financial resources to co-fund the
Development Costs and a detailed plan under which Myogen will have the financial resources
to undertake co-promotion of the Drug Products, including the requisite sales force and
sales force infrastructure required to provide its share of the promotional efforts. NIBRI
may require documentary and other evidence that Myogen has, or will have at the appropriate
time, the requisite resources (including personnel) and expertise to perform such
co-promotion, including satisfying the same percentage level of Co-Promotion Expenses and
promotional effort (including sales force details). Each Co-

[..**..] Confidential Treatment Requested

18

 

Promotion Response shall contain a commitment by Myogen that Myogen will be able to
satisfy its portion of the projected levels of Co-Promotion Expenses and promotional effort,
which may be satisfied initially or partially through use of a contract sales force;
provided, however, that oversight of the contract sales force will be
provided by Myogen sales management personnel. NIBRI may reject the Co-Promotion Response
(and the corresponding co-promotion opportunity with Myogen) only if it has reasonable
grounds based on such information that Myogen will not have such capability at the
appropriate time.

     (c) NIBRI and Myogen shall enter into good faith negotiations and will use reasonable
best efforts to conclude a co-funding/co-promotion definitive agreement (the “Definitive
Agreement”). The Definitive Agreement will outline the overall framework for the
co-promotion effort, including roles and responsibilities, total Co-Promotion Expenses
required and Myogen’s co-promotion funding commitment in the United States and, if
applicable, the European Countries that is at a percentage level identical to the
Co-Promotion Share and the European Co-Promotion Share, respectively. The Definitive
Agreement shall reflect, among other things, the following:

     (i) Given the expertise of NIBRI and its Affiliates in sales and marketing,
NIBRI shall have sole authority to determine the required budget of the Development
Program and the Co-Promotion Expenses and the total levels of promotional effort
(including sales force details) for such Drug Product, with Myogen’s input taking
into account Myogen’s expertise in the heart failure and cardiovascular market and
its Co-Promotion Share.

     (ii) Myogen shall be required under the Definitive Agreement to share a portion
of the Co-Promotion Expenses incurred by both NIBRI and Myogen, taken together, and
to provide the portion of the promotional effort (including sales force details) in
the Cardiac Field or the Expanded Cardiovascular Field, as applicable, equal to the
Co-Promotion Share with respect to the United States, and the European Co-Promotion
Share with respect to the European Countries.

[..**..] Confidential Treatment Requested

19

 

     (iii) Myogen shall be entitled to receive a portion of the Gross Contribution
derived from sales of the relevant Drug Product in the United States equal to the
Co-Promotion Share, and in [..**..], equal to the [..**..]
Co-Promotion Share, and NIBRI’s royalty obligations to Myogen under this Agreement
shall cease with respect to United States and, if applicable, the European
Countries.

     (iv) In consideration of the rights granted to Myogen under the Definitive
Agreement, Myogen will be required to pay NIBRI: (A) the Development Costs expended
by NIBRI as of the effective date of the Definitive Agreement that are attributable
to the development of the Development Candidate in the Cardiac Field or the Expanded
Cardiovascular Field, as applicable, in the United States and, if applicable, the
European Countries multiplied by the Co-Promotion Share (the “Expense
Reimbursement”); plus (B) a risk premium equal to the Expense Reimbursement
multiplied by [..**..]. These payments will be made in [..**..]
installments on the effective date of the Definitive Agreement and on
[..**..] the Definitive Agreement, regardless of the status of the
Development Program.

     (v) If Myogen is unable to satisfy its co-funding and co-promotion obligations
under the Definitive Agreement, or if Myogen elects to terminate its co-promotion
rights during the term of the Definitive Agreement, then Myogen’s share of the Gross
Contribution will be proportionately reduced taking into account Myogen’s
contribution to the co-funding and, if applicable, the commercialization of the
Drug Product, to be more fully specified in the Definitive Agreement.

     (vi) Additional terms and conditions customary in the industry for an agreement
of this type.

     (d) In no event shall any portion of Myogen’s co-funding commitment be provided by a
Third Party (not including any funding obtained by Myogen through loans or capital
investment by Third Parties) without the consent of NIBRI.

[..**..] Confidential Treatment Requested

20

 

     (e) Upon exercising its option to co-promote, Myogen will be allowed to appoint up to
[..**..] on NIBRI’s (or its Affiliate’s) International Project Team for the
Development Candidates or Drug Products that are under development by NIBRI hereunder and
will have access to project summaries and other documents provided by NIBRI to other members
of the International Project Team.

ARTICLE IV

Milestone and Royalty Payments

     4.1. Milestone Payments.

     (a) NIBRI shall make milestone payments to Myogen in accordance with this Section 4.1
with respect to Active Compounds developed as Development Candidates hereunder. Except as
explicitly set forth below, pre-clinical milestone payments shall be payable on only one
Active Compound per Myogen Target or Collaboration Target, and clinical milestones shall be
payable only once on a particular Active Compound, even though that Active Compound may be
subsequently developed for indications other than those for which Regulatory Approval was
initially sought. In the event that an Active Compound fails in development, any milestone
payments previously paid with respect to such Active Compound shall be fully creditable
toward the same milestone due with respect to another Active Compound that acts on the same
Myogen Target or Collaboration Target. NIBRI may deduct from any milestone payments
otherwise due to Myogen under this Article IV the amount of any withholding and similar
taxes required under applicable law to be withheld from such payments and paid to applicable
tax authorities.

     (b) The following milestone payments shall be payable within [..**..] of the
relevant developmental event:

[..**..] Confidential Treatment Requested

21

 

	 	 	 	 	 	 	 
	 	 	 	 	 	 	MILESTONE
	 	 	DEVELOPMENTAL MILESTONE:	 	PAYMENT
	Pre-Clinical Milestones:	 	 
	 
	 	 	 	 	 	 
	 

	 	•
	 	Validation of high-throughput assays*
	 	[..**..]
	 
	 	 	 	 	 	 
	 

	 	•
	 	In vitro validation of lead compound*
	 	[..**..]
	 
	 	 	 	 	 	 
	 

	 	•
	 	In Vivo Validation of lead compound or use
of the lead compound as a starting point for
medicinal chemistry and/or SAR exploration*
	 	[..**..]
	 
	 	 	 	 	 	 
	 

	 	•
	 	Completion of Tox/ADME screening and
preclinical candidate determination*
	 	[..**..]
	 
	 	 	 	 	 	 
	Clinical Milestones:	 	 
	 
	 	 	 	 	 	 
	 

	 	•
	 	IND filing
	 	[..**..]
	 
	 	 	 	 	 	 
	 

	 	•
	 	Initiation of Phase II clinical evaluation
	 	[..**..]
	 
	 	 	 	 	 	 
	 

	 	•
	 	Initiation of Phase III clinical studies
	 	[..**..]
	 
	 	 	 	 	 	 
	 

	 	•
	 	Regulatory filing in the U.S.
	 	[..**..]
	 
	 	 	 	 	 	 
	 

	 	•
	 	First regulatory filing in the E.U.
	 	[..**..]
	 
	 	 	 	 	 	 
	 

	 	•
	 	Regulatory Approval in the U.S.
	 	[..**..]
	 
	 	 	 	 	 	 
	 

	 	•
	 	First Regulatory Approval in the E.U.
	 	[..**..]

 

			
	*	 	Criteria for determining the achievement of any Milestone have been established by the JSC and
distributed to the parties under separate cover.

     4.2. Royalty Payments During the Patent Period. During the Patent Period (as defined in
Section 8.1 hereof), NIBRI shall make the following royalty payments to Myogen on total annual Net
Sales to unaffiliated Third Parties of each Drug Product incorporating an Active Compound that is
developed as a Development Candidate hereunder: [..**..] of Net Sales, plus: (a)
compensation for Third Party royalties owed by Myogen to the University of Texas Southwestern
Medical Center and the University of North Texas Health Sciences Center of up to

[..**..] Confidential Treatment Requested

22

 

[..**..] of Net Sales; and (b) compensation for Third Party royalties owed by Myogen
to University Licensing and Equity Holdings, Inc. of up to [..**..] of Net Sales, only to
the extent that such royalty obligations are incurred in connection with such Development
Candidate.

     4.3. Royalty Payments During a Know-How Period. During a Know-How Period (as defined in
Section 8.1 hereof), and in consideration for NIBRI’s license of the Myogen Know-How related to the
Development Candidate, NIBRI shall pay a [..**..] royalty to Myogen on total annual Net
Sales to unaffiliated Third Parties of each Drug Product incorporating an Active Compound that is
developed as a Development Candidate hereunder; provided, however, that no period
during which a Licensed Patent covers such Active Compound shall be deemed to be a Know-How Period,
in which case no royalty pursuant to this Section 4.3 shall be due to Myogen at any time.
Subsequent to the Expiration Date, the license of such Myogen Know-How shall be considered to be
perpetual and fully paid.

     4.4. Responsibility for Myogen’s Third Party Royalty Obligations. Myogen shall have sole
responsibility for payment of all its Third Party royalty obligations.

     4.5. Reduced Royalty Obligations. The obligation of NIBRI to pay royalties to Myogen under
this Agreement shall be reduced upon the occurrence of the following events:

     (a) In the event of Myogen’s material breach of this Agreement, which shall remain
uncured one hundred eighty (180) days after written notice by NIBRI to Myogen of the same,
NIBRI may, at its election, pay [..**..] of the royalties thereafter owed to Myogen
under this Article IV into a third party escrow account to be held pending resolution of the
dispute between NIBRI and Myogen by a court of competent jurisdiction. NIBRI may satisfy
any final, non-appealable judgment awarded by such court from the then-current balance of
the escrow account, and any excess of some or all of the escrow account will be promptly
refunded to Myogen; provided that this Section 4.5(a) will not limit any
compensatory or punitive damages that are recoverable at law or equity by NIBRI for Myogen’s
breach hereof.

     (b) In the event that no Live Claim in a particular country exists covering the
Development Candidate NIBRI’s royalty payment obligations under this Agreement in

[..**..] Confidential Treatment Requested

23

 

such jurisdiction shall be reduced to [..**..] should a Third Party generic
compound enter the market in such particular jurisdiction with respect to a such Development
Candidate.

     (c) All Third Party royalties and license fees owed by Myogen to any Myogen licensors
under agreements with such Third Party or Third Parties with respect to a Development
Candidate licensed hereunder shall be Myogen’s responsibility, subject to the provisions of
Section 9.3(b) hereof. In the event that NIBRI or an Affiliate thereof is required to pay
Third Party royalties or license fees in order to practice the License Patents for
applications in the Cardiac Field, NIBRI’s obligation to pay royalties to Myogen shall be
reduced by [..**..] of the amounts actually paid by NIBRI or its Affiliate to such
Third Party; provided, however, that NIBRI’s payment obligation shall in any
case not be reduced more than [..**..] of what otherwise would be owed to Myogen
hereunder.

     4.6. Certain Understandings Regarding Royalty Payments. The parties expressly agree that the
royalties and milestones hereunder are in consideration of the use of Myogen Technology to
identify, synthesize, select or find useful the Development Candidate as having a desired
therapeutic effect on any Myogen Target or Collaboration Target. Therefore, notwithstanding any
earlier expiration of the Licensed Patents, the term of payment of royalties hereunder is required
to compensate Myogen from revenues NIBRI or its Affiliates may in the future derive from such use
of the Myogen Technology and for the convenience of accounting.

ARTICLE V

Reporting Obligations

     5.1. Development Reports. NIBRI shall prepare and submit to Myogen, on a quarterly
basis, reports which set forth in reasonable detail the progress of the Development Program with
respect to Development Candidates and the results of work performed thereunder during the preceding
quarter.

     5.2. Sales Reports and Records. During the term of this Agreement, but only after the First
Commercial Sale of a Drug Product, NIBRI shall deliver to Myogen within forty-

[..**..] Confidential Treatment Requested

24

 

five (45) days after the end of each calendar quarter a written report showing actual Net
Sales of Drug Products by NIBRI, its Affiliates and sublicensees in each country in the Territory
during such calendar quarter. All Net Sales shall be stated in United States dollars, and shall
convert the amounts into United States dollars from the currency in which such amounts are received
by NIBRI using NIBRI’s then-current standard exchange rate methodology applied in its external
reporting for the translation of foreign currency sales into United States dollars. NIBRI will
keep complete, true and accurate books of account and records for the purpose of showing the
derivation of Net Sales and all amounts payable to Myogen under this Agreement. Such books and
records will be kept by NIBRI or an Affiliate of NIBRI for at least three (3) years following the
end of the calendar quarter to which they pertain. Such books and records, or copies thereof, will
be made available at NIBRI’s principal place of business, upon request of Myogen, for inspection
and copying by an independent auditor appointed by Myogen for the purpose of verifying NIBRI’s
sales reports or NIBRI’s compliance in other respects with this Agreement. Such inspections shall
be at the expense of Myogen, unless a variation or error exceeding five percent (5%) of the amount
reported is discovered in the course of any such inspection, whereupon the costs relating thereto
shall be for the account of NIBRI.

ARTICLE VI

Confidentiality

     6.1. Undertaking. During the term of this Agreement, each party (a “Receiving
Party”) shall keep confidential, and other than as provided herein shall not use or disclose,
directly or indirectly, any trade secrets, confidential or proprietary information, or any other
knowledge, information, documents or materials, owned, developed or possessed by the other party
(the “Proprietary Party”), whether in tangible or intangible form, the confidentiality of
which such other party takes reasonable measures to protect, including but not limited to
Collaboration Technology.

     (a) Each Receiving Party shall take any and all lawful measures to prevent the
unauthorized use and disclosure of such information, and to prevent unauthorized persons or
entities from obtaining or using such information.

[..**..] Confidential Treatment Requested

25

 

     (b) Each Receiving Party further agrees to refrain from directly or indirectly taking
any action that would constitute or facilitate the unauthorized use or disclosure of such
information. Each Receiving Party may disclose such information to its Affiliates and to
its or their respective officers, employees and agents, to authorized licensees and
sublicensees, and to subcontractors in connection with the development or manufacture of
Development Candidate or Drug Products, to the extent necessary to enable such parties to
perform their obligations hereunder or under the applicable license, sublicense or
subcontract, as the case may be; provided, that such officers, employees, agents, licensees,
sublicensees and subcontractors have entered into appropriate confidentiality agreements for
secrecy and non-use of such information which by their terms shall be enforceable by
injunctive relief at the instance of the Proprietary Party.

     (c) Each Receiving Party shall be liable for any unauthorized use and disclosure of
such information by its Affiliates or its or their respective officers, employees and agents
and any such sublicensees and subcontractors.

     6.2. Exceptions. Notwithstanding the foregoing, the provisions of Section 6.1 hereof shall
not apply to knowledge, information, documents or materials which the Receiving Party can
conclusively establish:

     (a) have entered the public domain without the Receiving Party’s breach of any
obligation owed to the Proprietary Party;

     (b) have become known to the Receiving Party from a source other than the Proprietary
Party, other than by breach of an obligation of confidentiality owed to the Proprietary
Party;

     (c) are independently developed by the Receiving Party without breach of this
Agreement, without reference to or reliance upon knowledge, information, or materials of the
Proprietary Party as established by written records; or

     6.3. In addition, a Receiving Party may, notwithstanding the obligations of Section 6.1,
disclose knowledge, information, documents or materials that the Receiving Party can conclusively
establish:

[..**..] Confidential Treatment Requested

26

 

     (a) are permitted to be disclosed by the prior written consent of the Proprietary
Party;

     (b) are required to be disclosed by the Receiving Party to comply with applicable laws
or regulations, to defend or prosecute litigation or to comply with governmental
regulations, provided that the Receiving Party provides prior written notice of such
disclosure to the Proprietary Party and takes reasonable and lawful actions to avoid or
minimize the degree of such disclosure.

     6.4. Publicity. The timing and content of any press releases or other public communications
relating to this Agreement and the transactions contemplated herein will, except as otherwise
required by law, be determined jointly by Myogen and NIBRI.

     6.5. Survival. The provisions of this Article VI shall survive the termination of this
Agreement.

ARTICLE VII

Patents

     7.1. Preparation. NIBRI shall take responsibility and pay for the preparation, filing,
prosecution and maintenance of: (a) any and all Patents in the Territory included in NIBRI
Patents, including without limitation any such patents and patent applications claiming NIBRI
Compounds or NIBRI Improvements under the Collaboration Agreement; (b) subsequent to the
Commencement Date with respect to Development Candidate, any and all Patents covering a Development
Candidate and any uses, formulations and formulation process inventions with respect thereto; and
(c) all Joint Patents. Myogen and NIBRI shall each furnish to the other party copies of
significant documents relevant to any such preparation, filing, prosecution or maintenance of
Patents covered by subsections (b) and (c) above. Myogen and NIBRI shall cooperate fully in the
preparation, filing, prosecution and maintenance of all Myogen Patents, NIBRI Patents, and Joint
Patents, executing all papers and instruments so as to enable the responsible party to apply for,
to prosecute and to maintain patent applications and patents in its name in any country in the
Territory. The parties acknowledge the importance of maintaining

[..**..] Confidential Treatment Requested

27

 

the confidentiality of any inventions or other information relating to potential patent claims
prior to the filing of patent applications with respect hereto. NIBRI shall provide Myogen prompt
notice as to any decision to abandon a Myogen Patent or a Joint Patent in a Listed Country.

     7.2. Infringement. Each party shall notify the other promptly of any possible infringements,
imitations or unauthorized possession, knowledge or use of the intellectual property embodied in
any of the Development Candidate and Myogen Know-How related to the manufacture or use of a
Development Candidate or Drug Products by Third Parties in any country in the Territory, of which
such party becomes aware. Each party shall promptly furnish the other party with full details of
such infringements, imitations or unauthorized possession, knowledge or use, and shall assist in
preventing any recurrence thereof. NIBRI or its Affiliates shall be initially responsible, at its
expense, for bringing any action on account of any such infringements, imitations or possession,
knowledge or use, and Myogen shall cooperate with NIBRI, as NIBRI may reasonably request, in
connection with any such action. If, within sixty (60) days after receipt by NIBRI of a written
request from Myogen that it bring such an action, NIBRI does not do so, Myogen shall have the
right, at its expense and in its own name or in the name of NIBRI, to do so on behalf of NIBRI, and
NIBRI shall cooperate with Myogen, as Myogen may reasonably request, in connection with such
action, including becoming a party to such suit. Such suit may not be settled by either party
without the other party’s written consent, which shall not be unreasonably withheld. Damages
recovered in any actions referenced hereunder shall be apportioned in accordance with the royalty
schedules contained in this Agreement, after reimbursement to each party of their respective
expenses in prosecuting such actions as provided hereunder.

ARTICLE VIII

Term and Termination

     8.1. Term. The patent period with respect to any Development Candidate or Drug Product
incorporating that Development Candidate (each, a “Patent Period”) shall extend in each
country of the Territory until the later of the last to expire of any Licensed Patents in that
country covering the Development Candidate or Drug Product incorporating that Development

[..**..] Confidential Treatment Requested

28

 

Candidate, the use thereof and/or the Myogen Target or the Collaboration Target on which the
Active Compound for the Development Candidate acts, or in the case of the European Countries, on a
country-by-country basis, the later of: (a) ten (10) years from the date of First Commercial Sale
of the Drug Product in that country; or (b) the last to expire of any Licensed Patents in that
country covering the Development Candidate or Drug Product. The know-how period with respect to
any Development Candidate or Drug Product incorporating that Development Candidate shall extend
after the First Commercial Sale in each country of the Territory for any period or periods not to
exceed five (5) years in the aggregate during which no Live Claim exists covering the Development
Candidate in such country (each a “Know-How Period”). Unless terminated earlier in
accordance with the provisions herein, this Agreement will expire, on a country-by-country basis,
upon the completion of the Patent Period and the Know-How Period (the “Expiration Date”).

     8.2. Material Breach by NIBRI. Upon any material breach of the provisions of this Agreement
or of the Collaboration Agreement by NIBRI, which material breach remains uncured by NIBRI one
hundred eighty (180) days after receipt of written notice of the same from Myogen, NIBRI’s
exclusive rights within the Territory shall become non-exclusive, and upon Myogen’s written
request, NIBRI shall thereupon render any reasonably necessary assistance to Myogen or its designee
to exercise Myogen’s rights within the Territory. The foregoing remedy shall not be exclusive, and
Myogen shall retain all other rights and remedies at law or equity for any such breach.

     8.3. Termination. Either Party may terminate this Agreement upon the bankruptcy or financial
insolvency of the other Party. NIBRI may terminate this Agreement without cause at any time upon
ninety (90) days written notice to Myogen.

     8.4. Effect of Termination. Termination of this Agreement for any reason, or expiration of
this Agreement, will terminate all rights and obligations of each of the Parties, and all license
rights granted to NIBRI and its Affiliates will terminate and revert exclusively to Myogen except
as otherwise provided below, and except that such termination or expiration will not affect: (a)
obligations, including the payment of any milestones or royalties, which have accrued as of the
date of termination or expiration; and (b) rights and obligations under the following provisions of
this Agreement, which shall survive termination or expiration of this

[..**..] Confidential Treatment Requested

29

 

Agreement: Article VI, Sections 9.1, 9.2, and 9.3. Following termination of this Agreement
under Section 8.1 hereof with respect to a particular country, NIBRI shall have a fully paid
license under the Myogen Technology to make, have made, use, sell, have sold and import for sale
Drug Product in that country in the Territory; provided however that NIBRI’s obligation to pay
royalties and milestone payments under Article IV shall continue after any termination of this
Agreement for the time periods specified in Section 8.1. NIBRI covenants that, upon and after
termination of this Agreement for any reason (other than expiration under Section 8.1), NIBRI and
its Affiliates and sublicensees shall not practice any of the Myogen Technology for any purpose
relating to any Development Compound (except as may otherwise expressly be permitted in a separate
agreement still in force between the Parties).

ARTICLE IX

Miscellaneous Provisions

     9.1. Governing Law, and Jurisdiction. This Agreement shall be governed and construed in
accordance with the internal laws of the Commonwealth of Massachusetts. Both parties hereto agree
to submit to personal jurisdiction in the Commonwealth of Massachusetts and to accept and agree to
venue in that Commonwealth.

     9.2. No Warranty. Myogen makes no warranty of any kind whatsoever, either express or implied,
to NIBRI, or any customer of NIBRI, as to the ability of NIBRI to understand and utilize the Myogen
Technology. NIBRI makes no warranty of any kind whatsoever, either express or implied, to Myogen,
or to any customer of Myogen, as to the ability of Myogen to understand and utilize the NIBRI
Technology. NIBRI shall indemnify and shall hold Myogen harmless against and from any and all
claims of Third Parties for damages due to personal injury arising out of the actions of NIBRI, its
Affiliates, agents, employees, sublicensees or subcontractors, including but not limited to claims
arising in connection with the development, manufacturing, assembly, or sale of Development
Candidates and Drug Products by NIBRI. Myogen shall indemnify and hold NIBRI harmless against and
from any and all claims of Third Parties for damages due to personal injury arising out of the
actions of Myogen, its Affiliates, agents, employees, sublicensees or subcontractors pursuant to
this Agreement, including but not

[..**..] Confidential Treatment Requested

30

 

limited to claims arising in connection with the Development Program in the Cardiac Field or
the Expanded Cardiovascular Field, as applicable. During the term of this Agreement, the Parties
shall keep each other promptly and fully informed and will promptly notify appropriate authorities
in accordance with applicable law, after receipt of information with respect to any serious adverse
event (as defined by the ICH Harmonized Tripartite Guideline on Clinical Safety Data Management),
directly or indirectly attributable to the use or application of Development Candidate or Drug
Product.

     9.3. Third Party Actions.

     (a) To Myogen’s knowledge, the exercise of the rights by NIBRI hereunder will not
result in the infringement of valid patents of Third Parties. Nevertheless, each party will
promptly notify the other in the event any relevant Third Party patents come to its notice.
Neither party gives a warranty to the other regarding the infringement of Third Party rights
by the development, manufacture, use or sale of the Development Candidate or the practice of
the Myogen Technology or the NIBRI Technology, and gives no indemnity against costs,
damages, expenses or other losses arising out of proceedings brought against the other party
or any other Person by any Third Party. In the event NIBRI is sued for infringement of any
rights of any Third Party in the course of its development, manufacture, marketing and sale
of Development Candidate in the Cardiac Field or its use of Myogen Technology in connection
therewith, Myogen shall extend to NIBRI, at no charge, good faith assistance and support in
defending such action, and may participate in the conduct of the suit at its own expense,
but shall otherwise be under no obligation in respect thereof. Legal expenses and fees
arising from such a legal action shall be paid by NIBRI.

     (b) In the event that the development of Development Candidate or the sale of a Drug
Product for indications within the Cardiac Field in any country necessarily involves working
within the scope of a Third Party’s patent, which would otherwise be infringed by the
practice of a Myogen Patent in connection with such development or sale, then Myogen will
use reasonable efforts to obtain required licenses under the Third Party’s patents, under
terms reasonably acceptable to both Myogen and NIBRI, and the terms of Section 4.5(c) hereof
shall apply; provided that neither Myogen nor NIBRI shall

[..**..] Confidential Treatment Requested

31

 

be required to accept any license which carries a financial obligation which is
materially in excess of the range of financial obligations customarily associated with
comparable non-exclusive licenses. If the terms of a required license under a Third Party
patent do not meet the foregoing requirements and Myogen therefore elects not to assume any
financial obligation, NIBRI may nonetheless elect to obtain the license, to continue sales
of Drug Product in such country and to pay, itself, any amounts due under such license. If
the required license is either unavailable or its terms are unacceptable both to Myogen and
to NIBRI, then NIBRI may elect in its sole discretion to discontinue sales of the Drug
Product in such country or at its sole expense to undertake the defense of a patent
infringement action or the prosecution of a declaratory judgment action with respect to the
Third Party patents.

     9.4. Force Majeure. Neither party will be in breach hereof by reason of its delay in the
performance of or failure to perform any of its obligations hereunder, if that delay or failure is
caused by strikes, acts of God or the public enemy, riots, incendiaries, interference by civil or
military authorities, compliance with governmental priorities for materials, or any fault beyond
its control or without its fault or negligence.

     9.5. Waiver. Any waiver by either party of the breach of any term or condition of this
Agreement will not be considered as a waiver of any subsequent breach of the same or any other term
or condition hereof.

     9.6. Severability. Should one or more provision of this Agreement be or become invalid, then
the parties hereto shall attempt in good faith to agree upon valid provisions in substitution for
the invalid provisions, which in their economic effect come so close to the invalid provisions that
it can be reasonably assumed that the parties would have accepted this Agreement with those new
provisions. If the parties are unable to agree on such valid provisions, the invalidity of such
one or more provisions of this Agreement shall nevertheless not affect the validity of this
Agreement as a whole, unless the invalid provisions are of such essential importance for this
Agreement that it may be reasonably presumed that the parties would not have entered into this
Agreement without the invalid provisions.

[..**..] Confidential Treatment Requested

32

 

     9.7. Government Acts. In the event that any act, regulation, directive, or law of a
government within the Territory, including its departments, agencies or courts, should make
impossible or prohibit, restrain, modify or limit any material act or obligation of NIBRI or Myogen
under this Agreement, the party, if any, not so affected, shall have the right, at its option, to
suspend or terminate this Agreement as to such country, if good faith negotiations between the
parties to make such modifications herein as may be necessary to fairly address the impact thereof,
after a reasonable period of time are not successful in producing mutually acceptable modifications
to this Agreement.

     9.8. Government Approvals. NIBRI or its sublicensees will obtain any government approval
required in the Territory to enable this Agreement to become effective, or to enable any payment
hereunder to be made, or any other obligation hereunder to be observed or performed. NIBRI will
keep Myogen informed of progress in obtaining any such government approval, and Myogen will
cooperate with NIBRI in any such efforts.

     9.9. Export Controls. This Agreement is made subject to any restrictions concerning the
export of Development Candidate or Myogen Technology from the United States that may be imposed
upon or related to either party to this Agreement from time to time by the Government of the United
States. Furthermore, NIBRI will not export, directly or indirectly, any Myogen Technology or any
Development Candidate utilizing such Myogen Technology to any countries for which the United States
Government or any agency thereof at the time of export requires an export license or other
governmental approval, without first obtaining the written consent to do so (of which NIBRI will
promptly inform Myogen) from the Department of Commerce or other agency of the United States
Government when required by applicable statute or regulation.

     9.10. Assignment. NIBRI may assign this Agreement, without the consent of Myogen:
(a) to any of its Affiliates; or (b) in connection with the transfer or sale of all or
substantially all of its assets or business or in the event of its merger or consolidation with
another company. Myogen may not assign or otherwise transfer this Agreement or any of its rights
or obligations under this Agreement without the prior written consent of NIBRI, except,
that Myogen may assign this Agreement to any Person in connection with a transaction which results
in the sale, merger, consolidation, transfer, or other reorganization of Myogen in which
substantially all of the assets of Myogen are transferred or in which the holders of Myogen’s
capital stock

[..**..] Confidential Treatment Requested

33

 

immediately prior to the transaction hold less than a majority of the capital stock of the
surviving entity after the transaction provided that should NIBRI demonstrate with
reasonable certainty that the proposed assignee is a significant competitor of NIBRI or its
Affiliates and Myogen’s proposed transaction would cause a material adverse effect on the
commercial potential of the Drug Product, then NIBRI will provide to Myogen written notice of such
determination within [..**..] specifying the reasons for such determination and, at
NIBRI’s election, the option to co-fund and co-promote Drug Products as set forth in Section 3.5
shall be unavailable to Myogen and such assignee. Any purported assignment in contravention of
this Section 9.10 shall, at the option of the nonassigning party, be null and void and of no
effect. No assignment shall release either party from responsibility for the performance of any
accrued obligation of such party hereunder. This Agreement shall be binding upon and enforceable
against the successor to or any permitted assignees from either of the parties hereto.

     9.11. Counterparts. This Agreement may be executed in duplicate, each of which shall be
deemed to be original and both of which shall constitute one and the same Agreement.

     9.12. No Agency. Nothing in this Agreement shall be deemed to create an agency, joint
venture, amalgamation, partnership or similar relationship between Myogen and NIBRI Notwithstanding
any of the provisions of this Agreement, neither party to this Agreement shall at any time enter
into, incur, or hold itself out to Third Parties as having authority to enter into or incur, on
behalf of the other party, any commitment, expense, or liability whatsoever, and all contracts,
expenses and liabilities in connection with or relating to the obligations of each party under this
Agreement shall be made, paid, and undertaken exclusively by such party on its own behalf and not
as an agent or representative of the other.

     9.13. Notice. All communications between the parties with respect to any of the provisions of
this Agreement will be sent to the addresses set out below or to other addresses as may be
designated by one party to the other by notice pursuant hereto, by prepaid certified mail (which
shall be deemed received by the other party on the seventh business day following deposit in the
mails), or by facsimile transmission or other electronic means of communication (which shall be
deemed received when transmitted), with confirmation by first class letter, postage pre-paid, given
by the close of business on or before the next following business day:

[..**..] Confidential Treatment Requested

34

 

if to NIBRI, at:

Novartis Institutes for BioMedical Research, Inc.

400 Technology Square

Cambridge, Massachusetts 02139

Attention: Robert L. Thompson, Vice President and General Counsel

Fax: (617) 871-3354

if to Myogen, at:

Myogen, Inc.

7575 West 103rd Avenue

Westminster, Colorado 80021

Attention: J. William Freytag, President and Chief Executive Officer

Fax: (303) 410-6667

with a copy to:

Myogen, Inc.

7575 W. 103rd Avenue

Westminster, Colorado 80021

Attention: Andrew D. Dickinson, Vice President and General Counsel

Fax: (303) 410-3350

     9.14. Headings. The paragraph headings are for convenience only and will not be deemed to
affect in any way the language of the provisions to which they refer.

     9.15. Authority. The undersigned represent that they are authorized to sign this Agreement on
behalf of the parties hereto. The parties each represent that no provision of this Agreement will
violate any other agreement that a party may have with any other person or company. Each party has
relied on that representation in entering into this Agreement.

     9.16. Entire Agreement. This Agreement contains the entire understanding of the parties
relating to the matters referred to herein, and may only be amended by a written document, duly
executed on behalf of the respective parties.

[..**..] Confidential Treatment Requested

35

 

	 	 	 	 	 	 	 	 	 
	 	 	MYOGEN, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Date of Signature:	 	 
	 

	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	NOVARTIS INSTITUTES FOR BIOMEDICAL	 	 
	 	 	RESEARCH, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Date of Signature:	 	 
	 

	 	 	 	 	 	 	 	 

[..**..] Confidential Treatment Requested

36

 

Schedule 1.38

Listed Countries

 

	 	 	 	 	 
	Albania AL

	 	Algeria DZ
	 	Antigua and Barbuda AG
	Argentina

	 	Armenia AM
	 	Australia AU
	Austria AT

	 	Azerbaijan AZ
	 	Barbados BB
	Belarus BY

	 	Belgium BE
	 	Belize BZ
	Benin BJ

	 	Bosnia and Herzegovina BA
	 	Botswana BW
	Brazil BR

	 	Bulgaria BG
	 	Burkina Faso BF
	Cameroon CM

	 	Canada CA
	 	Central African Republic CF
	Chad TD

	 	Chile
	 	China CN
	Colombia CO

	 	Congo CG
	 	Costa Rica CR
	Côte d’Ivoire CI

	 	Croatia HR
	 	Cuba CU
	Cyprus CY

	 	Czech Republic CZ
	 	Democratic People’s
Republic of Korea KP
	Denmark DK

	 	Dominica DM
	 	Ecuador EC
	Egypt EG

	 	Equatorial Guinea GQ
	 	Estonia EE
	Finland FI 2

	 	France FR
	 	Gabon GA
	Gambia GM

	 	Georgia GE
	 	Germany DE
	Ghana GH

	 	Greece GR
	 	Grenada GD
	Guinea GN

	 	Guinea-Bissau GW
	 	Hong Kong
	Hungary HU

	 	Iceland IS
	 	India IN
	Indonesia ID

	 	Ireland IE
	 	Israel IL
	Italy IT

	 	Japan JP
	 	Kazakhstan KZ 1
	Kenya KE

	 	Kyrgyzstan KG
	 	Latvia LV
	Lesotho LS

	 	Liberia LR
	 	Liechtenstein LI
	Lithuania LT

	 	Luxembourg LU
	 	Madagascar MG
	Malawi MW

	 	Malaysia
	 	Mali ML
	Mauritania MR

	 	Mexico MX
	 	Monaco MC
	Mongolia MN

	 	Morocco MA
	 	Mozambique MZ
	Netherlands NL 4

	 	New Zealand NZ
	 	Nicaragua NI
	Niger NE

	 	Norway NO
	 	Oman OM
	Pakistan

	 	Papua New Guinea PG
	 	Peru
	Philippines PH

	 	Poland PL
	 	Portugal PT
	Republic of Korea KR

	 	Republic of Moldova MD
	 	Romania RO
	Russian Federation RU

	 	Saint Lucia LC
	 	Saint Vincent and the
Grenadines VC
	Saudi Arabia

	 	Senegal SN
	 	Serbia and Montenegro CS
	Seychelles SC

	 	Sierra Leone SL
	 	Singapore SG
	Slovakia SK

	 	Slovenia SI
	 	South Africa ZA
	Spain ES

	 	Sri Lanka LK
	 	Sudan SD
	Swaziland SZ

	 	Sweden SE
	 	Switzerland CH
	Syrian Arab Republic SY

	 	Taiwan
	 	Tajikistan TJ
	Thailand

	 	The former Yugoslav
Republic of Macedonia MK
	 	Togo TG
	Trinidad and Tobago TT

	 	Tunisia TN
	 	Turkey TR
	Turkmenistan TM

	 	Uganda UG
	 	Ukraine UA
	United Arab Emirates AE

	 	United Kingdom GB
	 	United Republic of
Tanzania TZ
	United States of America US

	 	Uruguay
	 	Uzbekistan UZ
	Venezuela

	 	Viet Nam VN
	 	Zambia ZM
	Zimbabwe ZW
	 	 	 	 

[..**..] Confidential Treatment Requested

 

 

Schedule 1.42

Myogen Patents

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Schedule 1.42 Myogen Patents
	PATENTS	 	Filing Date	 	App. No.	 	Country	 	Pat. No.	 	Issue Date	 	Subject Matter
	MYOG:004-USD1
	 	4/25/2000	 	09/558,472	 	U.S.	 	 	 	 	 	Alpha Myosin Heavy Chain Gene Therapy
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:004-USD2
	 	10/1/2001	 	09/969,086	 	U.S.	 	7,049,066	 	5/23/2006	 	Alpha Myosin Heavy Chain Therapeutic/Screening
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:004-USD3
	 	2/25/2005	 	11/067,502	 	U.S.	 	 	 	 	 	Alpha Myosin Heavy Chain Treatment
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:004-WO
	 	1/30/1998	 	PCT/US98/01983	 	PCT	 	 	 	 	 	Alpha Myosin Heavy Chain
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:004-CA
	 	7/29/1999	 	2,278,465	 	Canada	 	 	 	 	 	Alpha Myosin Heavy Chain
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:004-EP
	 	7/30/1999	 	98906089.2	 	Europe	 	 	 	 	 	Alpha Myosin Heavy Chain
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:004-JP
	 	7/30/1999	 	10-533182	 	Japan	 	 	 	 	 	Alpha Myosin Heavy Chain
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:005-US
	 	4/1/1998	 	09/053,293	 	U.S.	 	6,218,597	 	4/17/2001	 	Transgenic mice w/cardiac specific promoters
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:006-US
	 	9/26/1997	 	08/938,105	 	U.S.	 	6,353,151	 	3/5/2002	 	Transgeneic alpha myosin
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:006-EP
	 	5/24/1999	 	97943597.1	 	Europe	 	 	 	 	 	Alpha Myosin Transgenes
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:007-US
	 	5/26/1998	 	09/047,755	 	U.S.	 	6,203,776	 	3/20/2001	 	Methods for identifying adrenergic receptors
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:013-US
	 	6/19/1998	 	09/100,497	 	U.S.	 	5,998,458	 	12/7/1999	 	Positive inotrope + beta adrenergic receptor antagonist
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:013-WO
	 	6/24/1998	 	PCT/US98/13442	 	PCT	 	 	 	 	 	Positive inotrope + beta adrenergic receptor antagonist
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:013-AU
	 	1/6/2000	 	81740/98	 	Australia	 	731,656	 	7/19/2001	 	Positive inotrope + beta adrenergic receptor antagonist
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:013-CA
	 	12/23/1999	 	2,295,094	 	Canada	 	 	 	 	 	Positive inotrope + beta adrenergic receptor antagonist
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:013-EP
	 	1/25/2000	 	198,931,687	 	Europe	 	 	 	 	 	Positive inotrope + beta adrenergic receptor antagonist
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:013-JP
	 	12/27/1999	 	11-505056	 	Japan	 	 	 	 	 	Positive inotrope + beta adrenergic receptor antagonist
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:020-US
	 	10/15/1998	 	09/173,798	 	U.S.	 	6,201,165	 	3/13/2001	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:020-WO
	 	10/16/1998	 	PCT/US98/21988	 	PCT	 	 	 	 	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:020-AU
	 	4/16/2000	 	10992/99	 	Australia	 	755428	 	8/16/2002	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:020-CA
	 	4/16/2000	 	2,315,244	 	Canada	 	 	 	 	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:020-EP
	 	4/16/2000	 	98953672.7	 	Europe	 	 	 	 	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:020-JP
	 	4/16/2000	 	2000-516026	 	Japan	 	 	 	 	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:020-MX
	 	4/14/2000	 	0003678	 	Mexico	 	 	 	 	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:023-US
	 	10/15/1998	 	09/173,795	 	U.S.	 	6,673,768	 	1/6/2004	 	Calcineurin Therapies
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:024-US
	 	11/10/1999	 	09/438,075	 	U.S.	 	6,372,957	 	4/16/2002	 	MEF2 methods of treatment
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:024-USC1
	 	1/9/2002	 	10/043,658	 	U.S.	 	 	 	 	 	MEF2 screening methods
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:024-WO
	 	11/10/1999	 	PCT/US99/26725	 	PCT	 	 	 	 	 	MEF2
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:024-CA
	 	5/7/2001	 	2,350,086	 	Canada	 	 	 	 	 	MEF2
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:024-EP
	 	5/21/2001	 	99971848.9	 	Europe	 	 	 	 	 	MEF2
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:024-JP
	 	5/10/2001	 	2000-581187	 	Japan	 	 	 	 	 	MEF2
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:025-US
	 	10/15/1998	 	09/173,799	 	U.S.	 	6,657,104	 	12/2/2003	 	Calcineurin transgenics
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:026-US
	 	8/20/2000	 	09/643,206	 	U.S.	 	6,632,628	 	8/20/2000	 	HDAC screening and treatment
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:026-USD1
	 	8/20/2003	 	10/637,403	 	U.S.	 	 	 	 	 	HDAC transgenics
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:026-WO
	 	8/20/2000	 	PCT/US00/22958	 	PCT	 	 	 	 	 	Class II HDACs
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:026-CA
	 	2/14/2002	 	2,382,045	 	Canada	 	 	 	 	 	Class II HDACs
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:026-EP
	 	3/13/2002	 	00955805.7	 	Europe	 	 	 	 	 	Class II HDACs
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:026-JP
	 	2/19/2002	 	2001-518892	 	Japan	 	 	 	 	 	Class II HDACs
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:028-US
	 	7/18/2001	 	09/908,988	 	U.S.	 	6,740,751	 	5/25/2004	 	Muscle Ring Finger Proteins (MURFS) Screening and Treatment
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:028-USD1
	 	2/10/2004	 	10/775,627	 	U.S.	 	7,005,512	 	2/28/2006	 	Muscle Ring Finger Proteins (MURFS) Screening and Treatment
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:028-USD2
	 	2/10/2004	 	10/775,649	 	U.S.	 	issue fee	 	paid	 	Muscle Ring Finger Proteins (MURFS)
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:029-US
	 	4/16/1998	 	09/061,417	 	U.S.	 	 	 	 	 	NF-AT3 inhibitors
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:029-WO
	 	10/16/1998	 	PCT/US98/21845	 	PCT	 	 	 	 	 	NF-AT3 inhibitors
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:029-AU
	 	10/15/1998	 	98058/98	 	Australia	 	748334	 	9/12/2002	 	NF-AT3 inhibitors
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:029-CA
	 	4/10/2000	 	2,306,448	 	Canada	 	 	 	 	 	NF-AT3 inhibitors
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:029-EP
	 	5/16/2000	 	9895233.7	 	Europe	 	 	 	 	 	NF-AT3 inhibitors
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:029-JP
	 	4/17/2000	 	2000-516024	 	Japan	 	 	 	 	 	NF-AT3 inhibitors

[..**..] Confidential Treatment Requested

 

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Schedule 1.42 Myogen Patents
	PATENTS	 	Filing Date	 	App. No.	 	Country	 	Pat. No.	 	Issue Date	 	Subject Matter
	MYOG:034-US
	 	9/26/2002	 	10/256,221	 	U.S.	 	6,707,686	 	3/16/2004	 	HDAC Inhibitors
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:034-USC1
	 	3/16/2004	 	10/801,985	 	U.S.	 	6,946,441	 	9/20/2005	 	Inhibiting HDACs
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:034-USC2
	 	7/26/2005	 	11/190,074	 	U.S.	 	 	 	 	 	Inhibiting HDACs
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:034-USC3
	 	8/30/2005	 	11/215,844	 	U.S.	 	 	 	 	 	Inhibiting HDACs
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:034-EP
	 	9/27/2001	 	02/021678.8	 	Europe	 	1,297,851	 	1/26/2005	 	Inhibiting HDACs
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:034-EPD1
	 	1/25/2005	 	5001443	 	Europe	 	 	 	 	 	Inhibiting HDACs
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:034-JP
	 	9/27/2001	 	2002-284313	 	Japan	 	 	 	 	 	Inhibiting HDACs
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:035-US
	 	1/21/2003	 	10/348,598	 	U.S.	 	 	 	 	 	Hypertrophic Cell Line
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:036-US
	 	2/13/2001	 	09/782,953	 	U.S.	 	 	 	 	 	MCIP’s screening, treatment, transgenics, antibodies
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:036-WO
	 	2/13/2001	 	PCT/US01/21662	 	PCT	 	 	 	 	 	MCIP’s screening, treatment, transgenics, antibodies
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:036-CA
	 	1/24/2003	 	2,415,967	 	Canada	 	 	 	 	 	MCIP’s screening, treatment, transgenics, antibodies
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:036-EP
	 	2/5/2003	 	1952568.2	 	Europe	 	 	 	 	 	MCIP’s screening, treatment, transgenics, antibodies
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:036-JP
	 	12/26/2002	 	2002-509354	 	Japan	 	 	 	 	 	MCIP’s screening, treatment, transgenics, antibodies
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:037-US
	 	8/20/2003	 	10/644,659	 	U.S.	 	 	 	 	 	STARS screening, treatment, transgenics, antibodies
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:044-US
	 	5/21/2003	 	10/848,820	 	U.S.	 	 	 	 	 	PKD (HDAC Kinase I)
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:044-WO
	 	5/21/2003	 	PCT/US04/015715	 	PCT	 	 	 	 	 	PKD (HDAC Kinase I)
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:044-AU
	 	5/21/2003	 	2004249114	 	Australia	 	 	 	 	 	PKD (HDAC Kinase I)
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:044-BR
	 	5/21/2003	 	 	 	Brazil	 	 	 	 	 	PKD (HDAC Kinase I)
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:044-CA
	 	5/21/2003	 	 	 	Canada	 	 	 	 	 	PKD (HDAC Kinase I)
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:044-CN
	 	5/21/2003	 	 	 	China	 	 	 	 	 	PKD (HDAC Kinase I)
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:044-EP
	 	5/21/2003	 	 	 	Europe	 	 	 	 	 	PKD (HDAC Kinase I)
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:044-IN
	 	5/21/2003	 	 	 	India	 	 	 	 	 	PKD (HDAC Kinase I)
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:044-JP
	 	5/21/2003	 	 	 	Japan	 	 	 	 	 	PKD (HDAC Kinase I)
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:044-MX
	 	5/21/2003	 	 	 	Mexico	 	 	 	 	 	PKD (HDAC Kinase I)
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:045-US
	 	11/3/2004	 	10/980,612	 	U.S.	 	 	 	 	 	Alpha myocin modulating compound ‘R’ enatiomer
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:045-WO
	 	11/3/2004	 	PCT/US04/036569	 	PCT	 	 	 	 	 	Alpha myocin modulating compound ‘R’ enatiomer
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:046-US
	 	11/3/2004	 	10/980,605	 	U.S.	 	 	 	 	 	Alpha myocin modulating compound ‘S’ enatiomer
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:046-US
	 	11/3/2004	 	PCT/US04/036568	 	PCT	 	 	 	 	 	Alpha myocin modulating compound ‘S’ enatiomer
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:047-US
	 	11/13/2004	 	10/988,192	 	U.S.	 	 	 	 	 	TRP Channel
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:047-WO
	 	11/13/2004	 	PCT/US04/037858	 	PCT	 	 	 	 	 	TRP Channel
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:048-US
	 	12/23/2004	 	11/018,426	 	U.S.	 	 	 	 	 	5-HT2 receptors
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:048-WO
	 	12/23/2004	 	PCT/US04/042922	 	PCT	 	 	 	 	 	5-HT2 receptors
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:049-US
	 	12/23/2004	 	11/018,383	 	U.S.	 	 	 	 	 	5-HT2 receptor binding compounds
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:049-WO
	 	12/23/2004	 	PCT/US04/042921	 	PCT	 	 	 	 	 	5-HT2 receptor binding compounds
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:050-US
	 	2/2/2005	 	11/049,630	 	U.S.	 	 	 	 	 	PRK (HDAC kinase II)
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:050-WO
	 	2/2/2005	 	PCT/US05/002808	 	PCT	 	 	 	 	 	PRK (HDAC kinase II)
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:054-US
	 	4/5/2005	 	11/099,417	 	U.S.	 	 	 	 	 	Nuclear export
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:054-WO
	 	4/5/2005	 	PCT/US05/011264	 	PCT	 	 	 	 	 	Nuclear export
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:057-WO
	 	9/19/2005	 	PCT/US05/033461	 	PCT	 	 	 	 	 	P38 MCIP
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:058-US
	 	8/15/2005	 	11/203,828	 	U.S.	 	 	 	 	 	Ku
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:060-USP1
	 	7/13/2005	 	60/699,189	 	U.S.	 	 	 	 	 	Proteasome inhibitors
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MYOG:062-USP1
	 	11/18/2005	 	60/737,952	 	U.S.	 	 	 	 	 	CAMKII/Calpain/HDACs
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	UTSD:803-US
	 	5/30/2002	 	10/159,971	 	U.S.	 	6,924,415	 	8/2/2005	 	MEK5
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	USTD:803-USD1
	 	4/21/2005	 	11/089,425	 	U.S.	 	 	 	 	 	MEK5
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	UTSD:803-CA
	 	5/29/2002	 	2,384,907	 	Canada	 	 	 	 	 	MEK5
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	UTSD:803-JP
	 	11/22/2001	 	2001-358595	 	Japan	 	 	 	 	 	MEK5
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	USTD:1771-USP1
	 	5/3/2006	 	not yet assigned	 	U.S.	 	 	 	 	 	CAMTA

[..**..] Confidential Treatment Requestedexv10w41

 

Exhibit 10.41

[..**..] = Certain Confidential Information Contained 

in this Document, Marked by Brackets, Has Been 

Omitted and Filed Separately with the Securities 

and Exchange Commission Pursuant to rule 24b-2

 of the Securities Exchange Act of 1934, as Amended.

ExhibitA-2

LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

(For HDAC Inhibitor Compounds)

     This License, Development and Commercialization Agreement (this “Agreement”) is made
this                      day of                     , 200___ by and between Myogen, Inc. (“Myogen”), a Delaware
corporation with principal offices at 7575 West 103rd Avenue, Westminster, Colorado
80021, and Novartis Institutes for BioMedical Research, Inc. (“NIBRI”), a Delaware
corporation with principal offices at 400 Technology Square, Cambridge, Massachusetts 02139.

     Capitalized terms used but not defined in this Agreement have the meanings provided in the
Collaboration Agreement.

Introduction

     WHEREAS, pursuant to the Collaboration Agreement, Myogen and NIBRI are, or have been,
engaged in discovering and developing compounds having a specific therapeutic effect on the Myogen
Targets (as defined in the Collaboration Agreement);

     WHEREAS, NIBRI has exercised its Option under the Collaboration Agreement to license
exclusively one or more of the Development Candidates (as defined herein) for
development and commercialization in the Licensed Field (as defined herein) and in the Territory;

     NOW THEREFORE, in consideration of the foregoing premises, the parties agree as follows:

[..**..] Confidential Treatment Requested

1

 

ARTICLE I

Definitions

     1.1. “Active Compound” shall have the meaning set forth in the Collaboration Agreement.

     1.2. “Affiliate” shall have the meaning set forth in the Collaboration Agreement.

     1.3. “Cardiac Field” shall mean the research, treatment, prognosis, diagnosis, prophylaxis,
and monitoring of heart muscle disease.

     1.4. “Collaboration Agreement” shall mean that certain Collaboration and Option Agreement
dated as of October 8, 2003, as amended and restated on July 7, 2006 by and between Myogen and
NIBRI, and as amended or restated by Myogen and NIBRI from time-to-time thereafter.

     1.5. “Collaboration Compound” shall have the meaning set forth in the Collaboration Agreement.

     1.6. “Collaboration HDAC Inhibitor Compound” shall mean any HDAC Inhibitor Compound other than
a NIBRI HDAC Inhibitor Compound, including, without limitation, all derivatives and analogs of
Collaboration HDAC Inhibitor Compounds and all derivatives and analogs of NIBRI HDAC Inhibitor
Compounds that do not fall within the definition of NIBRI HDAC Inhibitor Compounds set forth below.
In no event, however, shall any In-Licensed NIBRI HDAC Inhibitor Compound (as defined in Section
1.55(d) below) be a Collaboration HDAC Inhibitor Compound.

     1.7. [Reserved]

     1.8. “Commencement Date” shall mean, with respect to the application of this Agreement to a
Development Candidate, the date on which NIBRI exercised its Option under Section 4.4 of the
Collaboration Agreement with respect to that Development Candidate.

     1.9. “Compound” shall have the meaning set forth in the Collaboration Agreement.

     1.10. “Controlled” shall have the meaning set forth in the Collaboration Agreement.

[..**..] Confidential Treatment Requested

2

 

       1.11. “Co-Promotion Expenses” shall mean, with respect to each Drug Product, out-of-pocket
costs and other costs (in the case of personnel costs for personnel directly involved in the
marketing or promotional activities, excluding sales personnel and field service supervisors) which
are incurred by a party or any of its Affiliates solely in connection with marketing or promotional
activities in the Cardiac Field, including, without limitation, costs in the following categories
(in each case to the extent incurred in connection with activities in the Cardiac Field):

     (a) costs incurred in promoting and marketing such Drug Product, including without
limitation, advertising (including agency fees), market research, patient-oriented
promotions, meetings, pre-launch activities and expenses relating to launch of the Drug
Product, and managed markets/health authority liaisons (but excluding detailing expenses);

     (b) amounts repaid or credited for bad debts;

     (c) costs associated with post-marketing drug safety surveillance;

     (d) medical affairs costs, and costs associated with medical/scientific liaisons
(including regional scientific directors), medical education and publications, professional
symposia, advisory boards, speaker and activity programs;

     (e) costs of Phase IV Clinical Trials in the Territory and pharmacoeconomic studies;

     (f) the cost of samples;

     (g) costs of materials and programs for the training of sales force and marketing
management;

     (h) costs of promotional materials, telemarketing, e-marketing, field and headquarters’
grants, exhibits, direct mail and sample alternative programs;

     (i) all costs associated with the maintenance of Regulatory Approvals;

     (j) costs associated with any sales force training agreed to by NIBRI;
provided, however, that each party will train its own sales force (and that
of its Affiliates) at its own expense;

[..**..] Confidential Treatment Requested

3

 

     (k) amounts paid to a Third Party in order to obtain freedom to operate with respect to
such Drug Product in the Territory; and

 

     (l) amounts paid, whether in damages or by a settlement approved by NIBRI, to a Third
Party in the Territory as a result of any allegation of infringement by any party of a Third
Party patent by the manufacture, development or commercialization of such Drug Product.

 

     The foregoing shall not include any costs which: (i) are incurred prior to the Commencement
Date; (ii) are incurred in connection with the manufacture of any Drug Product; or (iii) have been
included in Development Costs or Regulatory Expenses.

     1.12. “Co-Promotion Notice” shall have the meaning set forth in Section 3.5(a) hereof.

     1.13. “Co-Promotion Response” shall have the meaning set forth in Section 3.5(a) hereof.

     1.14. “Co-Promotion Share” shall have the meaning set forth in Section 3.5(a) hereof.

     1.15. “Development Candidate” shall mean the HDAC Inhibitor Compound, together with the Myogen
Target on which it has therapeutic action, as to which NIBRI exercised its Option under the
Collaboration Agreement and has entered into this Agreement and any derivatives thereof whether or
not they were developed before or after the execution of this License Agreement.

     1.16. “Development Costs” shall mean, with respect to a Development Candidate and Drug
Products derived therefrom, expenses and other costs, including Regulatory Expenses
(except for the maintenance of Regulatory Approvals), incurred by or on behalf of a party in
connection with the worldwide development of such Development Candidate and Drug Products derived
therefrom in accordance with the Development Program in the Cardiac Field, including without
limitation the costs of clinical trials, the preparation, collation and/or validation of data from
such clinical trials and the preparation of medical writing as will make the results of such
clinical trials an element of one or more Registration Filings in the Cardiac Field;
provided, that Development Costs shall include: (a) the cost of any preclinical or
clinical studies conducted by

[..**..] Confidential Treatment Requested

4

 

NIBRI or its Affiliates in connection with a Development Program
outside the Cardiac Field (and not reimbursed or paid by a Third Party), to the extent the results
of such studies are required to be performed under applicable regulatory guidelines specific to the
indication being studied in the Cardiac Field and incorporated as part of any Registration Filings
submitted to support a Regulatory Approval for an indication in the Cardiac Field; and (b) the cost
of Phase IIIB clinical trials and Phase IV clinical trials only if and to the extent they are
intended to support indications in the Cardiac Field beyond the respective initial indications (as
agreed upon by the parties) for the Drug Products, to support expanded labeling for the Drug
Products, or to satisfy requirements imposed by governmental regulatory authorities in connection
with Regulatory Approvals for the Products in the Cardiac Field. Development Costs consist of:

     (a) all out-of-pocket costs incurred by the parties or their Affiliates, including
payments made to Third Parties with respect to any of the foregoing;

     (b) the fully allocated costs of internal scientific or technical personnel engaged in
such efforts, which costs shall be determined based on the FTE annual rate or such other
basis as may otherwise be agreed by the parties;

     (c) the costs of clinical supplies for such efforts as agreed in the applicable
approved Development Program in the Cardiac Field, including: (i) the fully allocated cost
or out-of-pocket costs, as applicable, incurred in purchasing and/or packaging comparator
drugs; and (ii) disposal of clinical samples;

     (d) the costs and expenses incurred in connection with technical development and with
other manufacturing development activities;

     (e) all amounts paid by NIBRI or its Affiliates to a Third Party to license, purchase
or otherwise acquire HDAC Inhibitor Compounds; and

     (f) any other costs or expenses explicitly included in the Development Program in the
Cardiac Field.

       1.17. “Development Program” shall mean activities associated with development of Active
Compounds as Development Candidates for sale as Drug Products in the Cardiac Field and in the
Territory, including but not limited to: (a) formulation of Active Compounds as

[..**..] Confidential Treatment Requested

5

 

Development
Candidates for use in preparation for preclinical studies; (b) preclinical animal studies performed
in accordance with GLP (or the applicable equivalent) in preparation for the filing of an IND (or
the applicable equivalent); (c) formulation and manufacture of Active Compounds as Development
Candidates for preclinical and clinical studies; (d) planning, implementation, evaluation and
administration of human clinical trials; (e) manufacturing process development and scale-up for the
manufacture of bulk Active Compound and Drug Product; (f) preparation and submission of
applications for regulatory approval; and (g) post-market surveillance of approved drug
indications, as required or agreed as part of a marketing approval by any governmental regulatory
authority.

     1.18. “Drug Product” shall mean a product prepared from bulk Active Compound with respect to a
Development Candidate, in finished dosage form ready for administration to the ultimate consumer as
a pharmaceutical.

     1.19. “European Co-Promotion Share” shall be equal to: (a) [..**..] of the
Co-Promotion Share for the first year following the commercial launch of the Drug Product in any of
the European Countries; (b) [..**..] of the Co-Promotion Share for the second year
following the commercial launch of the Drug Product in any of the European Countries; and (c)
[..**..] of the Co-Promotion Share for the third and each successive year following the
commercial launch of the Drug Product in any of the European Countries.

     1.20. “European Countries” shall mean the United Kingdom, Germany, France, Italy and Spain.

     1.21. “Expiration Date” shall have the meaning set forth in Section 8.1 hereof.

     1.22. “First Amendment Date” shall mean May 23, 2005.

     1.23. “First Commercial Sale” shall mean the first shipment of a Drug Product to a Third Party
by NIBRI or an Affiliate or sublicensee of NIBRI in a country in the Territory following applicable
Regulatory Approval of the Drug Product in such country.

     1.24. “GCP” shall mean the current Good Clinical Practice standards for clinical trials for
pharmaceuticals, as set forth in the Food, Drug and Cosmetic Act and applicable regulations
promulgated thereunder, as amended from time to time, and such standards of good clinical

[..**..] Confidential Treatment Requested

6

 

practice
as are required by the regulatory authorities of the organizations and governmental agencies in
countries in which Drug Products are intended to be sold.

     1.25. “GLP” shall mean the current Good Laboratory Practices regulations promulgated by the
FDA, published at 21 CFR Part 58, as such regulations may be from time to time amended, and such
equivalent regulations or standards of countries outside the United States as may be applicable to
activities conducted hereunder.

     1.26. “GMP” shall mean the current Good Manufacturing Practice regulations promulgated by the
FDA, published at 21 CFR Part 210 et seq., as such regulations may be amended, and such equivalent
foreign regulations or standards as may be applicable with respect to bulk Active Compound or a
Drug Product manufactured or sold outside the United States.

     1.27. “Gross Contribution” means, with respect to Drug Products co-promoted by the parties in
accordance with Section 3.5 hereof, [..**..] in the United States and/or the European
Countries (as applicable), less the following:

     (a) [..**..]; and

     (b) [..**..].

     1.28. “HDAC” shall mean any histone deacetylase protein.

     1.29. “HDAC Inhibitor Compound” shall mean any Active Compound that has a specific, desired
therapeutic action through its ability to bind directly to an HDAC and inhibit HDAC activity.

     1.30. “IC50” shall mean the concentration of a compound that reduces activity of an
enzyme by 50% in a standard, validated assay.

     1.31. “Improvement” means any enhancement in the formulation, ingredients, preparation,
presentation, means of delivery, dosage, packaging of, manufacture, or any new or expanded
therapeutic indication(s) for, an Active Compound, a Drug Product, or any other metabolite or
isomer thereof.

     1.32. “Improvement Patent” means any Patent containing claims that cover an Improvement.

[..**..] Confidential Treatment Requested

7

 

     1.33. “IND” shall mean an application to the Food and Drug Administration, the filing of which
is necessary to commence clinical testing of Compounds in humans, or the equivalent application to
the equivalent agency in any other country or group of countries.

     1.34. “In Vivo Validation” means, with respect to an Active Compound, the achievement of
physiologically significant activity in an appropriate in vivo model or models, where the level of
physiological significance and the in vivo model(s) to be used will be specified by the JSC with
respect to High Priority Targets and Low Priority Targets and by Myogen with respect to
Extra-Collaboration Targets.

     1.35. “Joint Know-How” shall mean Know-How that is owned or Controlled jointly by NIBRI or a
NIBRI Affiliate, on the one hand, and Myogen or a Myogen Affiliate, on the other hand.

     1.36. “Joint Patent” shall mean a Patent which, absent rights thereunder, would be infringed
by the research, development, manufacture, use, importation, sale, or distribution of the
Development Candidate or a Drug Product relating thereto, and is owned or Controlled jointly by
NIBRI or a NIBRI Affiliate, on the one hand, and Myogen or a Myogen Affiliate, on the other hand.

     1.37. “Joint Technology” shall mean Joint Patents and Joint Know-How.

     1.38. “Know-How” means all Technology other than inventions that are the subject of Patents,
including, but not limited to, information, technical information, techniques, data, inventions,
discoveries, trade secrets, processes, practices, methods, materials, compositions,
formulas, improvements, knowledge, know-how, skill, experience, or test data, whether or not
patented or confidential, which is Controlled by a party relating to the Myogen Technology or the
development, manufacture, use, sale, offer for sale, or import of any Active Compound, Development
Candidate, or Drug Product, or any Improvement thereto, including (but not limited to),
pharmacological, toxicological, pre-clinical and clinical test data, analytical and quality control
data, packaging, marketing, pricing, distribution, sales and manufacturing data or descriptions,
compositions-of-matter, assays and biological materials related thereto and the content of this
Agreement.

     1.39. “Know-How Period” shall have the meaning set forth in Section 8.1.

[..**..] Confidential Treatment Requested

8

 

     1.40. “Licensed Field” shall mean all human and veterinary health care applications including,
but not limited to, research, prognosis and diagnosis (subject to Section 2.5), therapeutics,
prophylaxis, and monitoring with respect to any indication, together with all agricultural
purposes.

     1.41. “Licensed Patents” shall mean any Myogen Patents that become the subject of NIBRI’s
rights under Article II of this Agreement upon exercise of its license and development option in
accordance with the provisions of Section 4.4 of the Collaboration Agreement.

     1.42. “Listed Country” shall mean a country listed on Schedule 1.42 hereof, as Schedule 1.42
may be amended from time to time on mutual written agreement of the parties.

     1.43. “Live Claim” shall mean a claim of any issued, unexpired Licensed Patent that shall not
have been withdrawn, canceled or disclaimed, nor held invalid or unenforceable by a court of
competent jurisdiction in an unappealed or unappealable decision.

     1.44. “Myogen Compound” shall have the meaning set forth in the Collaboration Agreement.

     1.45. “Myogen Know-How” shall have the meaning set forth in the Collaboration Agreement, as
the same shall exist on the Commencement Date and at any time during the term of this Agreement.

     1.46. “Myogen Patents” shall have the meaning set forth in the Collaboration Agreement, as in
effect on the Commencement Date and at any time during the term of this
Agreement. A list of Myogen Patents is appended hereto as Schedule 1.46 and will be updated
periodically to reflect additions thereto during the course of this Agreement.

     1.47. “Myogen Target” shall have the meaning set forth in the Collaboration Agreement.

     1.48. “Myogen Technology” shall mean all Myogen Patents and Myogen Know-How.

     1.49. “NDA” means a New Drug Application submitted to the Food and Drug Administration seeking
approval to market and sell a Drug Product in the Licensed Field in the United States of America,
or a corresponding application filed with any other regulatory agency

[..**..] Confidential Treatment Requested

9

 

seeking approval to market
and sell a Drug Product in the Licensed Field in a country in the Territory.

     1.50. “Net Sales” shall mean, with respect to a Drug Product, the gross amount invoiced by
NIBRI and any NIBRI Affiliate, sublicensee or marketing partner to Third Party customers for the
Drug Product, less:

     (a) Normal and customary trade and quantity discounts and non-affiliated brokers’ or
agents’ commissions actually allowed and taken and not already reflected in the amount
invoiced;

 

     (b) Amounts repaid or credited by reason of defects, rejections, returns, recalls,
allowances, or retroactive price reductions;

 

     (c) Third Party cash rebates and chargebacks related to sales of finished Drug
Products, to the extent allowed;

     (d) Retroactive price reductions that are actually allowed or granted;

     (e) Tariffs, duties, excise, sales, value-added, and other consumption taxes and
customs duties to the extent included in the invoice price and paid by or on behalf of
NIBRI;

     (f) Cash discounts for timely payment;

     (g) Delayed ship order credits;

     (h) Discounts pursuant to indigent patient programs and patient discount programs of
any nature;

     (i) A fixed charge of [..**..] to cover warehousing and distribution expenses;
and

     (j) Any other specifically identifiable costs or charges included in the gross invoiced
sales price of such Drug Product falling within categories substantially equivalent to those
listed above;

provided that:

[..**..] Confidential Treatment Requested

10

 

     (i) In the case of any sale or other disposal of a Drug Product between or
among NIBRI and its Affiliates, sublicensees or marketing partners, for resale, Net
Sales shall be calculated as above only on the value charged or invoiced on the
first arm’s length sale to a Third Party;

     (ii) In the case of any sale or other disposal, such as barter or
counter-trade, of any Drug Product, or part thereof, otherwise than in an arm’s
length transaction exclusively for money, Net Sales shall be calculated as above on
the value of the consideration received or, if higher, on the fair market price of
the Drug Product in the relevant country of sale or disposal; and

     (iii) In the event that a Drug Product is sold as part of a combination
product, Net Sales of the Drug Product, for the purpose of determining royalty
payments, shall be determined by multiplying Net Sales (as defined above) of the
combination product by the fraction A/(A+B), where A is the weighted (by sales
volume) average sales price of the Drug Product when sold separately in finished
form and B is the weighted average sale price of the other product(s) sold
separately in finished form. In the event that such average sales price cannot be
determined for both the Drug Product and the other product(s) in combination, Net
Sales for purposes of determining payments hereunder shall be mutually agreed by the
parties based on the relative value contributed by each component, and such
agreement shall not be unreasonably withheld.

     1.51. “NIBRI Compound” shall have the meaning set forth in the Collaboration Agreement.

     1.52. “NIBRI Know-How” shall have the meaning set forth in the Collaboration Agreement, as the
same shall exist on the Commencement Date and at any time during the term of this Agreement with
respect to the Development Candidate, any Drug Product incorporating the same, and their respective
use and manufacture.

     1.53. “NIBRI Patents” shall have the meaning set forth in the Collaboration Agreement, as in
effect on the Commencement Date and at any time during the term of this Agreement.

[..**..] Confidential Treatment Requested

11

 

     1.54. “NIBRI Technology” shall mean all NIBRI Patents and NIBRI Know-How.

     1.55. “NIBRI HDAC Inhibitor Compound” shall mean any of the following:

     (a) Except as otherwise provided in Section 3.6 of this Agreement, a HDAC Inhibitor
Compound first synthesized by NIBRI or its Affiliates outside of the collaboration
contemplated by the Collaboration Agreement and for which NIBRI or its Affiliates have
received or have applied for or could reasonably expect to apply for and receive U.S.
composition of matter patent coverage and that: (a) is shown to have an IC50 of
less than or equal to 1 mM (micromolar) in any standard NIBRI in vitro assay for the
inhibition of HDAC activity; and (b) has been designated a “Lead Series” candidate for
follow-up under the designation “Research Phase D3” in accordance with the standard drug
development terminology used by NIBRI; and

     (b) Except as otherwise provided in Section 3.6 of this Agreement, a HDAC Inhibitor
Compound licensed to, purchased or otherwise acquired by NIBRI or its Affiliates from a
Third Party for which (i) NIBRI or its Affiliates do not have any material future license,
royalty or similar payment obligations (as determined in good faith by the JSC), and (ii)
the Third Party licensor or assignor or NIBRI or its Affiliates have received or have
applied for or could reasonably expect to apply for and receive U.S. composition of matter
patent coverage and that (a) is shown to have an IC50 of less than or equal to 1
mM (micromolar) in any standard NIBRI in vitro assay for the inhibition of HDAC activity;
and (b) has been designated a “Lead Series” candidate for
follow-up under the designation “Research Phase D3” in accordance with the standard
drug development terminology used by NIBRI; and

     (c) Except as otherwise provided in Section 3.6 of this Agreement, all derivatives and
analogs of the compounds described in subsections (a) and (b) above that are shown to have
an IC50 of less than or equal to 100 nM (nanomolar) as determined by at least one
standard in vitro assay for the inhibition of HDAC activity; and

     (d) A HDAC Inhibitor Compound licensed to, purchased or otherwise acquired by NIBRI or
its Affiliates from a Third Party for which NIBRI or its Affiliates have any material future
license, royalty or similar payment obligation (as determined in

[..**..] Confidential Treatment Requested

12

 

good faith by the JSC) and
all derivatives and analogs of the compounds described in this subsection (d) for which
NIBRI or its Affiliates have any material future license, royalty or similar payment
obligation (as determined in good faith by the JSC) (collectively, “In-Licensed NIBRI HDAC
Inhibitor Compounds”).

     1.56. “Patent Period” shall have the meaning set forth in Section 8.1.

     1.57. “Patents” shall mean all existing patents and patent applications and all patent
applications hereafter filed, including any continuation, continuation-in-part, division,
provisional or any substitute applications, any patent issued with respect to any such patent
applications, any reissue, reexamination, renewal or extension (including any supplementary
protection certificate) of any such patent, and any confirmation patent or registration patent or
patent of addition based on any such patent, and all foreign counterparts of any of the foregoing.

     1.58. “Person” shall mean any individual, corporation, partnership, association, limited
liability company, trust, unincorporated organization or government or political subdivision
thereof.

     1.59. “Phase I Clinical Trial” shall mean a clinical study, conducted in accordance with a
protocol approved by NIBRI of a Drug Product in human volunteers with the endpoint of determining
initial tolerance, safety and/or pharmacokinetic information in single dose, single ascending dose,
multiple dose and/or multiple ascending dose regimens.

     1.60. “Phase II Clinical Trial” shall mean a clinical study, conducted in accordance with a
protocol approved by NIBRI, of a Drug Product in patients to determine initial efficacy and dose
range finding.

     1.61. “Phase III Clinical Trial” shall mean a clinical study in patients, conducted in
accordance with a protocol approved by NIBRI, which protocol is designed to ascertain efficacy and
safety of a Drug Product for the purpose of preparing and submitting a filing for Regulatory
Approval in a particular country in the Territory.

     1.62. “Phase IV Clinical Trial” shall mean a clinical study initiated in a country after
receipt of Regulatory Approval for a Drug Product in such country.

[..**..] Confidential Treatment Requested

13

 

     1.63. “Registration Filing” shall mean, with respect to each Development Candidate or related
Drug Product, the submission to the relevant governmental regulatory authority of an appropriate
application seeking any Regulatory Approval, and shall include, without limitation, any marketing
authorization application, supplementary application or variation thereof, or any equivalent
applications.

     1.64. “Regulatory Approval” shall mean, with respect to a country in the Territory, all
authorizations by the appropriate governmental entity or entities necessary for commercial sale of
a Drug Product in that country including, without limitation and where applicable, approval of
labeling, price, reimbursement and manufacturing.

     1.65. “Regulatory Expenses” shall mean, with respect to a Development Candidate or related
Drug Product, all out-of-pocket costs and fully allocated costs incurred by or on behalf of a party
in connection with the preparation and filing of Registration Filings and the maintenance of
Regulatory Approvals.

     1.66. “Technology” shall mean all data, technical information, know-how, experience,
inventions (whether or not patented), trade secrets, processes and methods discovered, developed or
applied (with the consent of its owner) and Controlled by either party or its Affiliates, in
connection with performance by either party under the Research Program, or in connection with the
conduct of a Development Program, that relate to the research, development, utilization,
manufacture or use of Targets or Compounds.

     1.67. “Territory” shall mean [..**..].

     1.68. “Third Party” shall mean any Person that is not a party or an Affiliate of any party to
this Agreement.

ARTICLE II

Rights and Licenses

     2.1. NIBRI Rights. Subject to the other provisions of this Agreement, Myogen grants to
NIBRI and its Affiliates a license, exclusive even as to Myogen, with the right to sublicense,
under the Myogen Patents and the Myogen Know-How and in the Licensed Field, to research

[..**..] Confidential Treatment Requested

14

 

and have
researched, develop and have developed, make and have made, and use and have used the Development
Candidate and to research and have researched, develop and have developed, make and have made,
manufacture and have manufactured, use and have used, market and have marketed, distribute and have
distributed, sell and have sold, export and import for sale, and have exported or imported for
sale, Drug Products in each country in the Territory. NIBRI understands that the licenses granted
under this Agreement to certain Myogen Technology that has been licensed by Myogen pursuant to
agreements with the University of Texas Southwestern Medical Center, the University of North Texas
Health Sciences Center and the University Licensing and Equity Holdings, Inc. are subject to the
retained rights of such licensors to use such Myogen Technology for research, teaching and other
educationally-related, non-commercial purposes. Myogen retains all rights to Myogen Technology
except to the extent explicitly granted to NIBRI hereunder.

     2.2. Scope of Exclusivity; Diligence; Development Responsibility.

     (a) As long as NIBRI is using commercially reasonable efforts to diligently develop
and/or commercialize the Development Candidate in the Cardiac Field:

     (i) The licenses granted to NIBRI in Section 2.1 shall be effective also with
respect to any other Active Compound, and any derivative thereof, which falls under
the same Live Claim as an Active Compound constituting the Development Candidate
provided that all of the terms and conditions of this
Agreement (including royalty and milestone payments) shall apply to all such
other Active Compounds; and

     (ii) Myogen shall not develop, make, have made, use, market and sell, itself or
through a Third Party licensee, for use within the Licensed Field, any other Active
Compound, and any derivative thereof, which falls under the same Live Claim as an
Active Compound constituting the Development Candidate.

     (b) NIBRI shall be deemed to be using commercially reasonable efforts with respect to
the provisions of Section 2.1 and Section 3.4 if NIBRI or any of its Affiliates is actively
undertaking diligent, commercially reasonable efforts, similar to those used for other
products of NIBRI or its Affiliates that are of similar commercial potential, for the

[..**..] Confidential Treatment Requested

15

 

continuing development and the commercialization of the Development Candidate, and any
derivative thereof, in the Cardiac Field, including, without limitation, the development
and/or optimization and/or further characterization of Active Compounds, initiation and
conduct of clinical trials, submission of regulatory filings and commercial launch of Drug
Products in the Cardiac Field.

     (c)
Except as otherwise provided herein, NIBRI will have sole responsibility for, and
bear the cost of conducting, the Development Program with respect to each Development
Candidate and/or seeking Regulatory Approval of any Drug Product.

     2.3. Joint Inventions and Joint Patents. All inventions conceived of and reduced to practice
during the term of, or as a result of, this Agreement, jointly by employees or agents of Myogen or
its Affiliates, on one hand, and employees or agents of NIBRI or its Affiliates, on the other hand
(“Joint Inventions”) and all Patent applications and Patents claiming Joint Inventions,
shall be owned jointly by Myogen and NIBRI, and such Patent applications and Patents shall be
included within the Joint Patents. The rights of each party with respect to the Joint Technology
shall be determined in accordance with United States patent law as it applies to issues of joint
ownership of intellectual property as of the Effective Date of the Collaboration Agreement.

     2.4. Inventions Necessary to the License. If Myogen conceives and reduces to practice during
the term of this Agreement any new Technology relating to a Development Candidate or Drug Product
and covered by a Myogen Patent, or acquires or Controls (either on
the Effective Date or at any time during the term of this Agreement) any Patent on a
Technology, and such Technology is necessary to NIBRI’s exercise of its licensed rights in the
Cardiac Field, then the definition of Myogen Patent will be deemed to include such Patents that are
included within the licenses granted to NIBRI under this Agreement.

     2.5. Diagnostic and Prognostic Products. In the event that NIBRI desires to develop and
commercialize any diagnostic or prognostic products based upon any Development Candidate, the
parties agree to negotiate in good faith the terms under which NIBRI would be granted rights to
develop and commercialize such products.

[..**..] Confidential Treatment Requested

16

 

ARTICLE III

Development and Commercialization

     3.1. Development and Commercialization Rights. Subject to any co-funding/co-promotion
rights granted to Myogen pursuant to Section 3.5 hereof, NIBRI, its Affiliates and/or sublicensees,
if any, shall have sole rights, even as to Myogen, in the Licensed Field to develop and manufacture
on a commercial scale the Development Candidate, and any derivative thereof, the related Drug
Product, and the active ingredient in such Drug Product in the Territory, and to commercialize,
manufacture, promote, sell, book sales, and distribute each Drug Product and/or the active
ingredient in such Drug Product in each country in the Territory. (The foregoing right to
manufacture is subject to any applicable United States statutory requirement that technology the
development of which was funded in part by the United States government must be manufactured
domestically, unless the United States government shall waive such requirement.) NIBRI and its
Affiliates, in their sole discretion, shall select, file, and own all rights to any and all
trademarks and trade dress relating to the Drug Product.

     3.2. Information Transfer. Myogen shall deliver (to the extent not previously delivered to
NIBRI pursuant to the Collaboration Agreement) as promptly as practicable to NIBRI all information
in Myogen’s possession or under its control (including summaries of raw data from clinical studies
conducted by Myogen of each Active Compound and related Myogen Target comprising the Development
Candidate), all scientific reports, and all processes and procedures that are necessary or useful
for further development, manufacture and commercial
exploitation and distribution of the Development Candidate in the Territory. Such information
shall include a summary of all material written communications (copies of which Myogen will provide
to NIBRI at NIBRI’s request) between Myogen or (to the extent available to Myogen) its other
licensees and the Food and Drug Administration (or any other similar regulatory authority)
concerning the Development Candidate. This information shall also include copies of all Patents,
copyrights, copyright registrations and applications therefor and all other manifestations of the
intellectual property embodied in the Development Candidate, whether in human or machine readable
form. Information provided by Myogen will be subject to the provisions of Article VI hereof.

[..**..] Confidential Treatment Requested

17

 

     3.3. Regulatory Approvals. NIBRI and/or its Affiliates will be responsible for all required
Regulatory Approvals in the Territory. All filings will be made by NIBRI and/or its Affiliates.
All Regulatory Approvals will be held in the name of NIBRI and/or its Affiliates. NIBRI and its
Affiliates shall have the right to cross-reference information and regulatory filings relating to
the Development Candidate arising out of development work which previously has been conducted by
Myogen and its Affiliates and licensees, for the purpose of regulatory filings hereunder.

     3.4. Due Diligence. Upon exercise of its Option with respect to a Development Candidate,
NIBRI and its Affiliates shall commence a Development Program in the Cardiac Field with respect to
such Development Candidate and shall use commercially reasonable efforts (as defined in Section
2.2(b)) to effect introduction of the Drug Product relating to such Development Candidate into one
or more commercial markets in the Territory for one or more indications within the Cardiac Field.
In the normal course of development, any Development Candidate may be dropped from development for
valid scientific or medical reasons provided to Myogen by NIBRI in writing and may be replaced (at
the sole discretion of NIBRI and/or its Affiliates) with another Development Candidate having a
therapeutic action on the same Myogen Target, and such occurrence shall not constitute a failure of
due diligence.

     3.5. Co-Funding and Co-Promotion Option.

       (a) With respect to any Development Candidate, and any derivative thereof, that is a
Collaboration HDAC Inhibitor Compound, upon the completion of Phase II
Clinical Trials with positive results leading to NIBRI’s reasonable expectation that it
will conduct Phase III Clinical Trials and generation of relevant reports, NIBRI will
provide Myogen with a report containing all relevant pre-clinical data and all relevant
clinical data from the Phase I Clinical Trials, the Phase II Clinical Trials and a
preliminary estimate of anticipated Co-Promotion Expenses (including sales force details)
(the “Co-Promotion Notice”). In the event that Myogen wishes to co-fund and
co-promote such Development Candidate in the Cardiac Field in either the United States, or
the United States and the European Countries, Myogen shall give NIBRI written notice of the
same no later than [..**..] after its receipt of the Co-Promotion Notice (the
“Co-Promotion Response”). The Co-Promotion Response will specify the level of
financial commitment

[..**..] Confidential Treatment Requested

18

 

that Myogen will assume with respect to the co-funding of such
Development Candidate and the co-promotion of such Development Candidate in the United
States in the Cardiac Field (the “Co-Promotion Share”); provided, that
Myogen shall be required to commit to fund no less than [..**..] and no greater
than [..**..] of the Development Costs and Co-Promotion Expenses of such
Development Candidate that are attributable to the development of the Development Candidate
in the Cardiac Field in the United States and, if applicable, the European Countries.

     (b) Along with the Co-Promotion Response, Myogen will provide NIBRI with certification
to NIBRI’s reasonable satisfaction that it has the financial resources to co-fund the
Development Costs and a detailed plan under which Myogen will have the financial resources
to undertake co-promotion of the Drug Products, including the requisite sales force and
sales force infrastructure required to provide its share of the promotional efforts. NIBRI
may require documentary and other evidence that Myogen has, or will have at the appropriate
time, the requisite resources (including personnel) and expertise to perform such
co-promotion, including satisfying the same percentage level of Co-Promotion Expenses and
promotional effort (including sales force details). Each Co-Promotion Response shall
contain a commitment by Myogen that Myogen will be able to satisfy its portion of the
projected levels of Co-Promotion Expenses and promotional effort, which may be satisfied
initially or partially through use of a contract sales force; provided,
however, that oversight of the contract sales force will be provided by Myogen sales
management personnel. NIBRI may reject the Co-Promotion Response (and the
corresponding co-promotion opportunity with Myogen) only if it has reasonable grounds
based on such information that Myogen will not have such capability at the appropriate time.

     (c) NIBRI and Myogen shall enter into good faith negotiations and will use reasonable
best efforts to conclude a co-funding/co-promotion definitive agreement (the “Definitive
Agreement”). The Definitive Agreement will outline the overall framework for the
co-promotion effort, including roles and responsibilities, total Co-Promotion Expenses
required and Myogen’s co-promotion funding commitment in the United States and, if
applicable, the European Countries that is at a percentage level identical to the
Co-

[..**..] Confidential Treatment Requested

19

 

Promotion Share and the European Co-Promotion Share, respectively. The Definitive
Agreement shall reflect, among other things, the following:

     (i) Given the expertise of NIBRI and its Affiliates in sales and marketing,
NIBRI shall have sole authority to determine the required budget of the Development
Program and the Co-Promotion Expenses and the total levels of promotional effort
(including sales force details) for such Drug Product, with Myogen’s input taking
into account Myogen’s expertise in the heart failure and cardiovascular market and
its Co-Promotion Share.

     (ii) Myogen shall be required under the Definitive Agreement to share a portion
of the Co-Promotion Expenses incurred by both NIBRI and Myogen, taken together, and
to provide the portion of the promotional effort (including sales force details) in
the Cardiac Field, equal to the Co-Promotion Share with respect to the United
States, and the European Co-Promotion Share with respect to the European Countries.

     (iii) Myogen shall be entitled to receive a portion of the Gross Contribution
derived from sales of the relevant Drug Product in the United States equal to the
Co-Promotion Share, and in [..**..], equal to the [..**..]
Co-Promotion Share, and NIBRI’s royalty obligations to Myogen under this Agreement
shall cease with respect to United States and, if applicable, the European
Countries.

     (iv) In consideration of the rights granted to Myogen under the Definitive
Agreement, Myogen will be required to pay NIBRI: (A) the Development Costs expended
by NIBRI as of the effective date of the Definitive Agreement that are attributable
to the development of the Development Candidate in the Cardiac Field in the United
States and, if applicable, the European Countries multiplied by the Co-Promotion
Share (the “Expense Reimbursement”); plus (B) a risk premium equal to the
Expense Reimbursement multiplied by [..**..]. These payments will be made
in [..**..] installments on the effective date

[..**..] Confidential Treatment Requested

20

 

of the Definitive Agreement
and on [..**..] the Definitive Agreement, regardless of the status of the
Development Program.

     (v) If Myogen is unable to satisfy its co-funding and co-promotion obligations
under the Definitive Agreement, or if Myogen elects to terminate its co-promotion
rights during the term of the Definitive Agreement, then Myogen’s share of the Gross
Contribution will be proportionately reduced taking into account Myogen’s
contribution to the co-funding and, if applicable, the commercialization of the Drug
Product, to be more fully specified in the Definitive Agreement.

     (vi) Additional terms and conditions customary in the industry for an agreement
of this type.

     (d) In no event shall any portion of Myogen’s co-funding commitment be provided by a
Third Party (not including any funding obtained by Myogen through loans or capital
investment by Third Parties) without the consent of NIBRI.

     (e) Upon exercising its option to co-promote, Myogen will be allowed to appoint up to
[..**..] on NIBRI’s (or its Affiliate’s) International Project Team for the
Development Candidates or Drug Products that are under development by NIBRI hereunder and
will have access to project summaries and other documents provided by NIBRI to other members
of the International Project Team.

     3.6. NIBRI HDAC Inhibitor Compounds.

     (a) With respect to any Development Candidate that is a NIBRI HDAC Inhibitor Compound
(and, therefore, not then subject to the co-promotion option described in Section 3.5), if,
at the time such Development Candidate has completed Phase II Clinical Trials sufficient for
proceeding into a Phase III Clinical Trial in the Cardiac Field, either: (i) the NIBRI HDAC
Inhibitor Compound has not entered first dosing in a GLP toxicology study intended to
support a Regulatory Filing for any indications outside the Cardiac Field; or (ii) NIBRI or
its Affiliates have terminated all active clinical development and/or commercialization of
such compound for any and all

[..**..] Confidential Treatment Requested

21

 

indications outside the Cardiac Field, then, at such time,
such NIBRI HDAC Inhibitor Compound will be deemed a Collaboration HDAC Inhibitor Compound
that will thereafter be subject to all of the terms of this Agreement applicable to a
Collaboration HDAC Inhibitor Compound, including the co-promotion option described in
Section 3.5 and the increased milestone and royalty payments described in Article IV hereof.
Notwithstanding the foregoing, any In-Licensed NIBRI HDAC Inhibitor Compound shall not be a
Collaboration HDAC Inhibitor Compound.

     (b) With respect to any Development Candidate that is a NIBRI HDAC Inhibitor Compound
other than a NIBRI HDAC Inhibitor Compound as described in subsection (a) above, if, within
[..**..] after such Development Candidate has completed Phase II Clinical Trials
sufficient for proceeding into a Phase III Clinical Trial in the Cardiac Field either: (i)
NIBRI or its Affiliates have terminated all active clinical development and/or
commercialization of such compound for any and all indications outside the Cardiac Field; or
(ii) further clinical development and/or commercialization of such compound has not been
funded by NIBRI or its Affiliates in the previous [..**..], then, at such time,
such NIBRI HDAC Inhibitor Compound will be deemed a Collaboration HDAC Inhibitor Compound
that will thereafter be subject to all of the terms of this Agreement applicable to a
Collaboration HDAC Inhibitor Compound, including the co-promotion option described in
Section 3.5 and the increased milestone and royalty payments described in Article IV hereof.
Notwithstanding the foregoing, any
In-Licensed NIBRI HDAC Inhibitor Compound shall not be a Collaboration HDAC Inhibitor
Compound.

ARTICLE IV

Milestone and Royalty Payments

     4.1. Milestone Payments.

     (a) NIBRI shall make milestone payments in accordance with this Section 4.1 with
respect to Active Compounds developed as Development Candidates hereunder. Except as
explicitly set forth below, pre-clinical milestone payments shall be payable on

[..**..] Confidential Treatment Requested

22

 

only one
Active Compound per Myogen Target, and clinical milestones shall be payable only once on a
particular Active Compound, even though that Active Compound may be subsequently developed
for indications other than those for which Regulatory Approval was initially sought. In the
event that an Active Compound fails in development, any milestone payments previously paid
with respect to such Active Compound shall be fully creditable toward the same milestone due
with respect to another Active Compound that acts on the same Myogen Target. NIBRI may
deduct from any milestone payments otherwise due to Myogen under this Article IV the amount
of any withholding and similar taxes required under applicable law to be withheld from such
payments and paid to applicable tax authorities.

     (b) The following milestone payments shall be payable within [..**..] of the
relevant developmental event corresponding to milestones achieved in a Development Program
for the Cardiac Field:

[..**..] Confidential Treatment Requested

23

 

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Future	 	 
	 	 	 	 	Prior Clinical	 	NIBRI	 	Collaboration
	 	 	 	 	NIBRI HDAC	 	HDAC	 	HDAC
	 	 	DEVELOPMENTAL	 	Inhibitor	 	Inhibitor	 	Inhibitor
	 	 	MILESTONE:	 	Compounds	 	Compounds	 	Compounds
	Pre-Clinical Milestones:	 	 	 	 	 	 
	•

	 	Validation of high-throughput
assays*
	 	[..**..]
	 	[..**..]
	 	[..**..]
	•

	 	In vitro validation of lead
compound*
	 	[..**..]
	 	[..**..]
	 	[..**..]
	•

	 	In Vivo Validation of lead
compound or use of the lead compound as a
starting point for medicinal chemistry
and/or SAR exploration*
	 	[..**..]
	 	[..**..]
	 	[..**..]
	•

	 	Additional payment at the earlier
of In Vivo Validation or second
(2nd) anniversary of the First
Amendment Date**
	 	[..**..]
	 	[..**..]
	 	[..**..]
	•

	 	Completion of Tox/ADME screening
and preclinical candidate determination*
	 	[..**..]
	 	[..**..]
	 	[..**..]
	 
	 	 	 	 	 	 	 	 
	Clinical Milestones:	 	 	 	 	 	 
	•

	 	IND filing
	 	[..**..]
	 	[..**..]
	 	[..**..]
	•

	 	Initiation of Phase II clinical
evaluation
	 	[..**..]
	 	[..**..]
	 	[..**..]
	•

	 	Initiation of Phase III clinical
studies
	 	[..**..]
	 	[..**..]
	 	[..**..]
	•

	 	Regulatory filing in the U.S.
	 	[..**..]
	 	[..**..]
	 	[..**..]
	•

	 	First regulatory filing in the
E.U.
	 	[..**..]
	 	[..**..]
	 	[..**..]
	•

	 	Regulatory Approval in the U.S.
	 	[..**..]
	 	[..**..]
	 	[..**..]
	•

	 	First Regulatory Approval in the
E.U.
	 	[..**..]
	 	[..**..]
	 	[..**..]

 

			
	*   Criteria for determining the achievement of any Milestone will be established by the JSC.

	 
	** For the avoidance of doubt, this milestone is payable only once.

     (c) For purposes of determining the milestone payments applicable to a NIBRI HDAC
Inhibitor Compound in the above table: (i) a “Prior Clinical NIBRI HDAC Inhibitor
Compound” means a NIBRI HDAC Inhibitor Compound for which NIBRI or its Affiliates have
submitted an IND with the FDA and initiated a Phase I Clinical Trial prior to the First
Amendment Date; and (ii) a “Future NIBRI HDAC Inhibitor Compound” means any NIBRI
HDAC Inhibitor Compound other than a Prior Clinical NIBRI HDAC Inhibitor Compound. For the
avoidance of doubt, any HDAC Inhibitor Compound, the rights to which are licensed or
otherwise acquired from a Third Party by NIBRI or its Affiliates, shall be considered to be
a Prior Clinical NIBRI HDAC Inhibitor Compound if such Third Party (or NIBRI or its
Affiliates) has submitted an IND

[..**..] Confidential Treatment Requested

24

 

with the FDA and initiated a Phase I Clinical Trial
covering such HDAC Inhibitor Compound prior to the date of such license or acquisition.

     (d) If a Development Candidate that was once a NIBRI HDAC Inhibitor Compound is
subsequently deemed to be Collaboration HDAC Inhibitor Compound pursuant to Section 3.6
hereof, NIBRI will pay to Myogen the difference between (i) all milestone payments that have
been made (or are then owing) pursuant to Section 4.1(b) prior to such event and (ii) the
milestones payments that would have been due for such milestones if the Development
Candidate had then been deemed a Collaboration HDAC Inhibitor Compound (the “Increased
Milestone Payments”). At Myogen’s option, the Increased Milestone Payments may be
credited against Myogen’s share of the Development Costs for such Collaboration HDAC
Inhibitor Compound that would be owed by Myogen if Myogen exercises its co-promotion option
for such compound. Otherwise, the Increased Milestone Payments shall be payable within
[..**..] after the reclassification of the Development Candidate as a Collaboration
HDAC Inhibitor Compound pursuant to Section 3.6 hereof.

     For the avoidance of doubt, no milestone payments on Prior Clinical NIBRI HDAC
Inhibitors and / or Future NIBRI HDAC Inhibitors shall be owed by NIBRI to Myogen for any
indications outside of the Cardiac Field.

     4.2. Royalty Payments During the Patent Period.

     (a) Collaboration HDAC Inhibitor Compounds. During the Patent Period (as
defined in Section 8.1 hereof), NIBRI shall make the following royalty payments to Myogen on
total annual Net Sales to unaffiliated Third Parties of each Drug Product incorporating an
Active Compound that is developed as a Development Candidate deemed to be a Collaboration
HDAC Inhibitor Compound hereunder: (i) [..**..] of Net Sales for all indications
in the Cardiac Field, plus compensation for Third Party royalties owed by Myogen to the
University of Texas Southwestern Medical Center, the University of North Texas Health
Sciences Center and University Licensing and Equity Holdings, Inc. of up to
[..**..] of such Net Sales in the aggregate, only to the extent that such royalty
obligations are incurred in connection with such Development Candidate;

[..**..] Confidential Treatment Requested

25

 

and (ii)
[..**..] of Net Sales for all indications outside the Cardiac Field, for which
Myogen will be responsible for all Third Party royalties owed on such Net Sales, if any.

     (b) NIBRI HDAC Inhibitor Compounds. During the Patent Period (as defined in
Section 8.1 hereof), NIBRI shall make the following royalty payments to Myogen on total
annual Net Sales to unaffiliated Third Parties of each Drug Product incorporating an Active
Compound that is developed as a Development Candidate deemed to be a NIBRI Inhibitor
Compound hereunder: (i) [..**..] of Net Sales of any Prior Clinical NIBRI HDAC
Inhibitor Compounds (as defined in Section 4.1(c) hereof) for all indications in the Cardiac
Field; or (ii) [..**..] of Net Sales of any Future NIBRI HDAC Inhibitor Compounds
(as defined in Section 4.1(c) hereof) for all indications in the Cardiac Field. For the
avoidance of doubt, no royalty payments shall be owed by NIBRI to Myogen for any indications
outside of the Cardiac Field. Myogen will be responsible for all Third Party royalties owed
on any Net Sales under this Section 4.2(b), if any. For the avoidance of doubt, any HDAC
Inhibitor Compound, the rights to which are licensed or otherwise acquired from a Third
Party by NIBRI or its Affiliates, shall be considered to be a Prior Clinical NIBRI HDAC
Inhibitor Compound if such Third Party (or NIBRI or
its Affiliates) has submitted an IND with the FDA and initiated a Phase I Clinical
Trial covering such HDAC Inhibitor Compound prior to the date of such license or
acquisition.

       4.3. Royalty Payments During a Know-How Period. During a Know-How Period (as defined in
Section 8.1 hereof), and in consideration for NIBRI’s license of the Myogen Know-How related to the
Development Candidate, NIBRI shall pay a [..**..] royalty to Myogen on total annual Net
Sales to unaffiliated Third Parties of each Drug Product incorporating a Collaboration HDAC
Inhibitor Compound that is developed as a Development Candidate hereunder; provided,
however, that no period during which a Licensed Patent covers such Collaboration HDAC
Inhibitor Compound shall be deemed to be a Know-How Period, in which case no royalty pursuant to
this Section 4.3 shall be due to Myogen at any time. Subsequent to the Expiration Date, the
license of such Myogen Know-How shall be considered to be perpetual and fully paid. 

       4.4. Responsibility for Myogen’s Third Party Royalty Obligations. Myogen shall have sole
responsibility for payment of all its Third Party royalty obligations.

[..**..] Confidential Treatment Requested

26

 

       4.5. Reduced Royalty Obligations. The obligation of NIBRI to pay royalties to Myogen under
this Agreement shall be reduced upon the occurrence of the following events:

     (a) In the event of Myogen’s material breach of this Agreement, which shall remain
uncured one hundred eighty (180) days after written notice by NIBRI to Myogen of the same,
NIBRI may, at its election, pay [..**..] of the royalties thereafter owed to Myogen
under this Article IV into a third party escrow account to be held pending resolution of the
dispute between NIBRI and Myogen by a court of competent jurisdiction. NIBRI may satisfy
any final, non-appealable judgment awarded by such court from the then-current balance of
the escrow account, and any excess of some or all of the escrow account will be promptly
refunded to Myogen; provided that this Section 4.5(a) will not limit any
compensatory or punitive damages that are recoverable at law or equity by NIBRI for Myogen’s
breach hereof.

     (b) In the event that no Live Claim exists in a particular country covering the
Development Candidate NIBRI’s royalty payment obligations under this Agreement in
such jurisdiction shall be reduced to [..**..] should a Third Party generic
compound enter the market in such particular jurisdiction with respect to a such Development
Candidate.

     (c) All Third Party royalties and license fees owed by Myogen to any Myogen licensors
under agreements with such Third Party or Third Parties with respect to a Development
Candidate licensed hereunder shall be Myogen’s responsibility, subject to the provisions of
Section 9.3(b) hereof. In the event that NIBRI or an Affiliate thereof is required to pay
Third Party royalties or license fees in order to practice the Licensed Patents for
applications in the Cardiac Field, NIBRI’s obligation to pay royalties to Myogen shall be
reduced by [..**..] of the amounts actually paid by NIBRI or its Affiliate to such
Third Party; provided, however, that NIBRI’s payment obligation shall in any
case not be reduced more than [..**..] of what otherwise would be owed to Myogen
hereunder.

       4.6. Certain Understandings Regarding Royalty Payments. The parties expressly agree that the
royalties and milestones hereunder are in consideration of the use of Myogen Technology to
identify, synthesize, select or find useful the Development Candidate as having a

[..**..] Confidential Treatment Requested

27

 

desired
therapeutic effect on any Myogen Target. Therefore, notwithstanding any earlier expiration of the
Licensed Patents, the term of payment of royalties hereunder is required to compensate Myogen from
revenues NIBRI or its Affiliates may in the future derive from such use of the Myogen Technology
and for the convenience of accounting.

ARTICLE V

Reporting Obligations

     5.1. Development Reports. NIBRI shall prepare and submit to Myogen, on a quarterly
basis, reports which set forth in reasonable detail the progress of the Development Program with
respect to Development Candidates and the results of work performed thereunder during the preceding
quarter.

     5.2. Sales Reports and Records. During the term of this Agreement, but only after the First
Commercial Sale of a Drug Product, NIBRI shall deliver to Myogen within forty-five (45) days after
the end of each calendar quarter a written report showing actual Net Sales of
Drug Products by NIBRI, its Affiliates and sublicensees in each country in the Territory
during such calendar quarter. All Net Sales shall be stated in United States dollars, and shall
convert the amounts into United States dollars from the currency in which such amounts are received
by NIBRI using NIBRI’s then-current standard exchange rate methodology applied in its external
reporting for the translation of foreign currency sales into United States dollars. NIBRI will
keep complete, true and accurate books of account and records for the purpose of showing the
derivation of Net Sales and all amounts payable to Myogen under this Agreement. Such books and
records will be kept by NIBRI or an Affiliate of NIBRI for at least three (3) years following the
end of the calendar quarter to which they pertain. Such books and records, or copies thereof, will
be made available at NIBRI’s principal place of business, upon request of Myogen, for inspection
and copying by an independent auditor appointed by Myogen for the purpose of verifying NIBRI’s
sales reports or NIBRI’s compliance in other respects with this Agreement. Such inspections shall
be at the expense of Myogen, unless a variation or error exceeding five percent (5%) of the amount
reported is discovered in the course of any such inspection, whereupon the costs relating thereto
shall be for the account of NIBRI.

[..**..] Confidential Treatment Requested

28

 

ARTICLE VI

Confidentiality

      6.1. Undertaking. During the term of this Agreement, each party (a “Receiving
Party”) shall keep confidential, and other than as provided herein shall not use or disclose,
directly or indirectly, any trade secrets, confidential or proprietary information, or any other
knowledge, information, documents or materials, owned, developed or possessed by the other party
(the “Proprietary Party”), whether in tangible or intangible form, the confidentiality of
which such other party takes reasonable measures to protect, including but not limited to
Collaboration Technology.

     (a) Each Receiving Party shall take any and all lawful measures to prevent the
unauthorized use and disclosure of such information, and to prevent unauthorized persons or
entities from obtaining or using such information.

     (b) Each Receiving Party further agrees to refrain from directly or indirectly taking
any action that would constitute or facilitate the unauthorized use or disclosure of such
information. Each Receiving Party may disclose such information to its Affiliates and to
its or their respective officers, employees and agents, to authorized licensees and
sublicensees, and to subcontractors in connection with the development or manufacture of
Development Candidate or Drug Products, to the extent necessary to enable such parties to
perform their obligations hereunder or under the applicable license, sublicense or
subcontract, as the case may be; provided, that such officers, employees, agents, licensees,
sublicensees and subcontractors have entered into appropriate confidentiality agreements for
secrecy and non-use of such information which by their terms shall be enforceable by
injunctive relief at the instance of the Proprietary Party.

     (c) Each Receiving Party shall be liable for any unauthorized use and disclosure of
such information by its Affiliates or its or their respective officers, employees and agents
and any such sublicensees and subcontractors.

[..**..] Confidential Treatment Requested

29

 

      6.2. Exceptions. Notwithstanding the foregoing, the provisions of Section 6.1 hereof shall
not apply to knowledge, information, documents or materials which the Receiving Party can
conclusively establish:

     (a) have entered the public domain without the Receiving Party’s breach of any
obligation owed to the Proprietary Party;

     (b) have become known to the Receiving Party from a source other than the Proprietary
Party, other than by breach of an obligation of confidentiality owed to the Proprietary
Party;

     (c) are independently developed by the Receiving Party without breach of this
Agreement, without reference to or reliance upon knowledge, information, or materials of the
Proprietary Party as established by written records; or

      6.3. In addition, a Receiving Party may, notwithstanding the obligations of Section 5.1,
disclose knowledge, information, documents or materials that the Receiving Party can conclusively
establish:

     (a) are permitted to be disclosed by the prior written consent of the Proprietary
Party;

     (b) are required to be disclosed by the Receiving Party to comply with applicable laws
or regulations, to defend or prosecute litigation or to comply with governmental
regulations, provided that the Receiving Party provides prior written notice of such
disclosure to the Proprietary Party and takes reasonable and lawful actions to avoid or
minimize the degree of such disclosure.

      6.4. Publicity. The timing and content of any press releases or other public communications
relating to this Agreement and the transactions contemplated herein will, except as otherwise
required by law, be determined jointly by Myogen and NIBRI.

      6.5. Survival. The provisions of this Article VI shall survive the termination of this
Agreement.

[..**..] Confidential Treatment Requested

30

 

ARTICLE VII

Patents

     7.1. Preparation. NIBRI shall take responsibility and pay for the preparation, filing,
prosecution and maintenance of: (a) any and all Patents in the Territory included in NIBRI
Patents, including without limitation any such patents and patent applications claiming NIBRI
Compounds or NIBRI Improvements under the Collaboration Agreement; (b) subsequent to the
Commencement Date with respect to Development Candidate, any and all Patents covering a Development
Candidate and any uses, formulations and formulation process inventions with respect thereto; and
(c) all Joint Patents. Myogen and NIBRI shall each furnish to the other party copies of
significant documents relevant to any such preparation, filing, prosecution or maintenance of
Patents covered by subsections (b) and (c) above. Myogen and NIBRI shall cooperate fully in the
preparation, filing, prosecution and maintenance of all Myogen Patents, NIBRI Patents, and Joint
Patents, executing all papers and instruments so as to enable the responsible party to apply for,
to prosecute and to maintain patent applications and patents in its name in any country in the
Territory. The parties acknowledge the importance of maintaining the confidentiality of any
inventions or other information relating to potential patent claims prior
to the filing of patent applications with respect hereto. NIBRI shall provide Myogen prompt
notice as to any decision to abandon a Myogen Patent or a Joint Patent in a Listed Country.

     7.2. Infringement. Each party shall notify the other promptly of any possible infringements,
imitations or unauthorized possession, knowledge or use of the intellectual property embodied in
any of the Development Candidate and Myogen Know-How related to the manufacture or use of a
Development Candidate or Drug Products by Third Parties in any country in the Territory, of which
such party becomes aware. Each party shall promptly furnish the other party with full details of
such infringements, imitations or unauthorized possession, knowledge or use, and shall assist in
preventing any recurrence thereof. NIBRI or its Affiliates shall be initially responsible, at its
expense, for bringing any action on account of any such infringements, imitations or possession,
knowledge or use, and Myogen shall cooperate with NIBRI, as NIBRI may reasonably request, in
connection with any such action. If, within sixty (60) days after receipt by NIBRI of a written
request from Myogen that it bring such an action,

[..**..] Confidential Treatment Requested

31

 

NIBRI does not do so, Myogen shall have the
right, at its expense and in its own name or in the name of NIBRI, to do so on behalf of NIBRI, and
NIBRI shall cooperate with Myogen, as Myogen may reasonably request, in connection with such
action, including becoming a party to such suit. Such suit may not be settled by either party
without the other party’s written consent, which shall not be unreasonably withheld. Damages
recovered in any actions referenced hereunder shall be apportioned in accordance with the royalty
schedules contained in this Agreement, after reimbursement to each party of their respective
expenses in prosecuting such actions as provided hereunder.

ARTICLE VIII

Term and Termination

     8.1. Term. The patent period with respect to any Development Candidate or Drug Product
incorporating that Development Candidate (each a “Patent Period”) shall extend in each
country of the Territory until the later of the last to expire of any Licensed Patents in that
country covering the Development Candidate or Drug Product incorporating that Development
Candidate, the use thereof and/or the Myogen Target on which the Active Compound for the
Development Candidate acts, or in the case of the European Countries, on a country-by-country
basis, the later of: (a) ten (10) years from the date of First Commercial Sale of the Drug Product
in that country; or (b) the last to expire of any Licensed Patents in that country covering the
Development Candidate or Drug Product. The know-how period with respect to any Development
Candidate or Drug Product incorporating that Development Candidate shall extend after the First
Commercial Sale in each country of the Territory for any period or periods not to exceed five (5)
years in the aggregate during which no Live Claim exists covering the Development Candidate in such
country (each a “Know-How Period”). Unless terminated earlier in accordance with the
provisions herein, this Agreement will expire, on a country-by-country basis, upon the completion
of the Patent Period and the Know-How Period (the “Expiration Date”).

     8.2. Material Breach by NIBRI. Upon any material breach of the provisions of this Agreement
or of the Collaboration Agreement by NIBRI, which material breach remains

[..**..] Confidential Treatment Requested

32

 

uncured by NIBRI one
hundred eighty (180) days after receipt of written notice of the same from Myogen, NIBRI’s
exclusive rights within the Territory shall become non-exclusive, and upon Myogen’s written
request, NIBRI shall thereupon render any reasonably necessary assistance to Myogen or its designee
to exercise Myogen’s rights within the Territory. The foregoing remedy shall not be exclusive, and
Myogen shall retain all other rights and remedies at law or equity for any such breach.

     8.3. Termination. Either Party may terminate this Agreement upon the bankruptcy or financial
insolvency of the other Party. NIBRI may terminate this Agreement without cause at any time upon
ninety (90) days written notice to Myogen.

     8.4. Effect of Termination. Termination of this Agreement for any reason, or expiration of
this Agreement, will terminate all rights and obligations of each of the Parties, and all license
rights granted to NIBRI and its Affiliates will terminate and revert exclusively to Myogen except
as otherwise provided below, and except that such termination or expiration will not affect: (a)
obligations, including the payment of any milestones or royalties, which have accrued as of the
date of termination or expiration; and (b) rights and obligations under the following provisions of
this Agreement, which shall survive termination or expiration of this Agreement: Article VI,
Sections 9.1, 9.2, and 9.3. Following termination of this Agreement
under Section 8.1 hereof with respect to a particular country, NIBRI shall have a fully paid
license under the Myogen Technology to make, have made, use, sell, have sold and import for sale
Drug Product in that country in the Territory; provided however that NIBRI’s obligation to pay
royalties and milestone payments under Article IV shall continue after any termination of this
Agreement for the time periods specified in Section 8.1. NIBRI covenants that, upon and after
termination of this Agreement for any reason (other than expiration under Section 8.1), NIBRI and
its Affiliates and sublicensees shall not practice any of the Myogen Technology for any purpose
relating to any Development Compound (except as may otherwise expressly be permitted in a separate
agreement still in force between the Parties).

[..**..] Confidential Treatment Requested

33

 

ARTICLE IX

Miscellaneous Provisions

      9.1. Governing Law, and Jurisdiction. This Agreement shall be governed and construed in
accordance with the internal laws of the Commonwealth of Massachusetts. Both parties hereto agree
to submit to personal jurisdiction in the Commonwealth of Massachusetts and to accept and agree to
venue in that Commonwealth.

      9.2. No Warranty. Myogen makes no warranty of any kind whatsoever, either express or implied,
to NIBRI, or any customer of NIBRI, as to the ability of NIBRI to understand and utilize the Myogen
Technology. NIBRI makes no warranty of any kind whatsoever, either express or implied, to Myogen,
or to any customer of Myogen, as to the ability of Myogen to understand and utilize the NIBRI
Technology. NIBRI shall indemnify and shall hold Myogen harmless against and from any and all
claims of Third Parties for damages due to personal injury arising out of the actions of NIBRI, its
Affiliates, agents, employees, sublicensees or subcontractors, including but not limited to claims
arising in connection with the development, manufacturing, assembly, or sale of Development
Candidates and Drug Products by NIBRI. Myogen shall indemnify and hold NIBRI harmless against and
from any and all claims of Third Parties for damages due to personal injury arising out of the
actions of Myogen, its Affiliates, agents, employees, sublicensees or subcontractors pursuant to
this Agreement, including but not limited to claims arising in connection with the Development
Program in the Cardiac Field.
During the term of this Agreement, the Parties shall keep each other promptly and fully
informed and will promptly notify appropriate authorities in accordance with applicable law, after
receipt of information with respect to any serious adverse event (as defined by the ICH Harmonized
Tripartite Guideline on Clinical Safety Data Management), directly or indirectly attributable to
the use or application of Development Candidate or Drug Product.

      9.3. Third Party Actions.

     (a) To Myogen’s knowledge, the exercise of the rights by NIBRI hereunder will not
result in the infringement of valid patents of Third Parties in the Cardiac Field.
Nevertheless, each party will promptly notify the other in the event any relevant Third
Party patents come to its notice. Neither party gives a warranty to the other regarding the

[..**..] Confidential Treatment Requested

34

 

infringement of Third Party rights by the development, manufacture, use or sale of the
Development Candidate or the practice of the Myogen Technology or the NIBRI Technology, and
gives no indemnity against costs, damages, expenses or other losses arising out of
proceedings brought against the other party or any other Person by any Third Party. In the
event NIBRI is sued for infringement of any rights of any Third Party in the course of its
development, manufacture, marketing and sale of Development Candidate in the Cardiac Field
or its use of Myogen Technology in connection therewith, Myogen shall extend to NIBRI, at no
charge, good faith assistance and support in defending such action, and may participate in
the conduct of the suit at its own expense, but shall otherwise be under no obligation in
respect thereof. Legal expenses and fees arising from such a legal action shall be paid by
NIBRI.

     (b) In the event that the development of Development Candidate or the sale of a Drug
Product for indications within the Cardiac Field in any country necessarily involves working
within the scope of a Third Party’s patent, which would otherwise be infringed by the
practice of a Myogen Patent in connection with such development or sale, then Myogen will
use reasonable efforts to obtain required licenses under the Third Party’s patents, under
terms reasonably acceptable to both Myogen and NIBRI, and the terms of Section 4.5(c) hereof
shall apply; provided that neither Myogen nor NIBRI shall be required to
accept any license which carries a financial obligation which is materially in excess of the
range of financial obligations customarily associated with comparable
non-exclusive licenses. If the terms of a required license under a Third Party patent
do not meet the foregoing requirements and Myogen therefore elects not to assume any
financial obligation, NIBRI may nonetheless elect to obtain the license, to continue sales
of Drug Product in such country and to pay, itself, any amounts due under such license. If
the required license is either unavailable or its terms are unacceptable both to Myogen and
to NIBRI, then NIBRI may elect in its sole discretion to discontinue sales of the Drug
Product in such country or at its sole expense to undertake the defense of a patent
infringement action or the prosecution of a declaratory judgment action with respect to the
Third Party patents.

[..**..] Confidential Treatment Requested

35

 

     9.4. Force Majeure. Neither party will be in breach hereof by reason of its delay in the
performance of or failure to perform any of its obligations hereunder, if that delay or failure is
caused by strikes, acts of God or the public enemy, riots, incendiaries, interference by civil or
military authorities, compliance with governmental priorities for materials, or any fault beyond
its control or without its fault or negligence.

     9.5. Waiver. Any waiver by either party of the breach of any term or condition of this
Agreement will not be considered as a waiver of any subsequent breach of the same or any other term
or condition hereof.

     9.6. Severability. Should one or more provision of this Agreement be or become invalid, then
the parties hereto shall attempt in good faith to agree upon valid provisions in substitution for
the invalid provisions, which in their economic effect come so close to the invalid provisions that
it can be reasonably assumed that the parties would have accepted this Agreement with those new
provisions. If the parties are unable to agree on such valid provisions, the invalidity of such
one or more provisions of this Agreement shall nevertheless not affect the validity of this
Agreement as a whole, unless the invalid provisions are of such essential importance for this
Agreement that it may be reasonably presumed that the parties would not have entered into this
Agreement without the invalid provisions.

     9.7. Government Acts. In the event that any act, regulation, directive, or law of a
government within the Territory, including its departments, agencies or courts, should make
impossible or prohibit, restrain, modify or limit any material act or obligation of NIBRI or
Myogen under this Agreement, the party, if any, not so affected, shall have the right, at its
option, to suspend or terminate this Agreement as to such country, if good faith negotiations
between the parties to make such modifications herein as may be necessary to fairly address the
impact thereof, after a reasonable period of time are not successful in producing mutually
acceptable modifications to this Agreement.

     9.8. Government Approvals. NIBRI or its sublicensees will obtain any government approval
required in the Territory to enable this Agreement to become effective, or to enable any payment
hereunder to be made, or any other obligation hereunder to be observed or performed.

[..**..] Confidential Treatment Requested

36

 

NIBRI will
keep Myogen informed of progress in obtaining any such government approval, and Myogen will
cooperate with NIBRI in any such efforts.

     9.9. Export Controls. This Agreement is made subject to any restrictions concerning the
export of Development Candidate or Myogen Technology from the United States that may be imposed
upon or related to either party to this Agreement from time to time by the Government of the United
States. Furthermore, NIBRI will not export, directly or indirectly, any Myogen Technology or any
Development Candidate utilizing such Myogen Technology to any countries for which the United States
Government or any agency thereof at the time of export requires an export license or other
governmental approval, without first obtaining the written consent to do so (of which NIBRI will
promptly inform Myogen) from the Department of Commerce or other agency of the United States
Government when required by applicable statute or regulation.

     9.10. Assignment. NIBRI may assign this Agreement, without the consent of Myogen:
(a) to any of its Affiliates; or (b) in connection with the transfer or sale of all or
substantially all of its assets or business or in the event of its merger or consolidation with
another company. Myogen may not assign or otherwise transfer this Agreement or any of its rights
or obligations under this Agreement without the prior written consent of NIBRI, except,
that Myogen may assign this Agreement to any Person in connection with a transaction which results
in the sale, merger, consolidation, transfer, or other reorganization of Myogen in which
substantially all of the assets of Myogen are transferred or in which the holders of Myogen’s
capital stock immediately prior to the transaction hold less than a majority of the capital stock
of the surviving entity after the transaction provided that should NIBRI
demonstrate with reasonable certainty that the proposed assignee is a significant competitor of
NIBRI or its Affiliates and Myogen’s
proposed transaction would cause a material adverse effect on the commercial potential of the
Drug Product, then NIBRI will provide to Myogen written notice of such determination within
[..**..] specifying the reasons for such determination and, at NIBRI’s election, the
option to co-fund and co-promote Drug Products as set forth in Section 3.5 shall be unavailable to
Myogen and such assignee. Any purported assignment in contravention of this Section 9.10 shall, at
the option of the nonassigning party, be null and void and of no effect. No assignment shall
release either party from responsibility for the performance of any accrued obligation of such
party

[..**..] Confidential Treatment Requested

37

 

hereunder. This Agreement shall be binding upon and enforceable against the successor to or
any permitted assignees from either of the parties hereto.

     9.11. Counterparts. This Agreement may be executed in duplicate, each of which shall be
deemed to be original and both of which shall constitute one and the same Agreement.

     9.12. No Agency. Nothing in this Agreement shall be deemed to create an agency, joint
venture, amalgamation, partnership or similar relationship between Myogen and NIBRI Notwithstanding
any of the provisions of this Agreement, neither party to this Agreement shall at any time enter
into, incur, or hold itself out to Third Parties as having authority to enter into or incur, on
behalf of the other party, any commitment, expense, or liability whatsoever, and all contracts,
expenses and liabilities in connection with or relating to the obligations of each party under this
Agreement shall be made, paid, and undertaken exclusively by such party on its own behalf and not
as an agent or representative of the other.

     9.13. Notice. All communications between the parties with respect to any of the provisions of
this Agreement will be sent to the addresses set out below or to other addresses as may be
designated by one party to the other by notice pursuant hereto, by prepaid certified mail (which
shall be deemed received by the other party on the seventh business day following deposit in the
mails), or by facsimile transmission or other electronic means of communication (which shall be
deemed received when transmitted), with confirmation by first class letter, postage pre-paid, given
by the close of business on or before the next following business day:

if to NIBRI, at:

Novartis Institutes for BioMedical Research, Inc.

400 Technology Square

Cambridge, Massachusetts 02139

Attention: Robert L. Thompson, Vice President and General Counsel

Fax: (617) 871-3354

if to Myogen, at:

Myogen, Inc.

7575 West 103rd Avenue

Westminster, Colorado 80021

Attention: J. William Freytag, President and Chief Executive Officer

Fax: (303) 410-6667

[..**..] Confidential Treatment Requested

38

 

with a copy to:

Myogen, Inc.

7575 W. 103rd Avenue

Westminster, Colorado 80021

Attention: Andrew D. Dickinson, Vice President and General Counsel

Fax: (303) 410-3350

     9.14. Headings. The paragraph headings are for convenience only and will not be deemed to
affect in any way the language of the provisions to which they refer.

     9.15. Authority. The undersigned represent that they are authorized to sign this Agreement on
behalf of the parties hereto. The parties each represent that no provision of this Agreement will
violate any other agreement that a party may have with any other person or company. Each party has
relied on that representation in entering into this Agreement.

     9.16. Entire Agreement. This Agreement contains the entire understanding of the parties
relating to the matters referred to herein, and may only be amended by a written document, duly
executed on behalf of the respective parties.

[..**..] Confidential Treatment Requested

39

 

	 	 	 	 	 	 	 	 	 
	 	 	MYOGEN, INC.
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	Title:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Date of Signature:	 	 	 	 
	 

	 	 	 	 	 	 

	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	NOVARTIS INSTITUTES FOR BIOMEDICAL
	 	 	RESEARCH, INC.
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	Title:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Date of Signature:	 	 	 	 
	 

	 	 	 	 	 	 

	 	 

[..**..] Confidential Treatment Requested

40

 

Schedule 1.42

Listed Countries

 

United States

Europe

Japan

 

 

Schedule 1.46

Myogen Patents

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Schedule 1.46 Myogen Patents
	PATENTS	 	Filing Date	 	App. No.	 	Country	 	Pat. No.	 	Issue Date	 	Subject Matter
	MYOG:004-USD1
	 	4/25/2000	 	09/558,472	 	U.S.	 	 	 	 	 	Alpha Myosin Heavy Chain Gene Therapy
	MYOG:004-USD2
	 	10/1/2001	 	09/969,086	 	U.S.	 	7,049,066	 	5/23/2006	 	Alpha Myosin Heavy Chain Therapeutic/Screening
	MYOG:004-USD3
	 	2/25/2005	 	11/067,502	 	U.S.	 	 	 	 	 	Alpha Myosin Heavy Chain Treatment
	MYOG:004-WO
	 	1/30/1998	 	PCT/US98/01983	 	PCT	 	 	 	 	 	Alpha Myosin Heavy Chain
	MYOG:004-CA
	 	7/29/1999	 	2,278,465	 	Canada	 	 	 	 	 	Alpha Myosin Heavy Chain
	MYOG:004-EP
	 	7/30/1999	 	98906089.2	 	Europe	 	 	 	 	 	Alpha Myosin Heavy Chain
	MYOG:004-JP
	 	7/30/1999	 	10-533182	 	Japan	 	 	 	 	 	Alpha Myosin Heavy Chain
	MYOG:005-US
	 	4/1/1998	 	09/053,293	 	U.S.	 	6,218,597	 	4/17/2001	 	Transgenic mice w/cardiac specific promoters
	MYOG:006-US
	 	9/26/1997	 	08/938,105	 	U.S.	 	6,353,151	 	3/5/2002	 	Transgeneic alpha myosin
	MYOG:006-EP
	 	5/24/1999	 	97943597.1	 	Europe	 	 	 	 	 	Alpha Myosin Transgenes
	MYOG:007-US
	 	5/26/1998	 	09/047,755	 	U.S.	 	6,203,776	 	3/20/2001	 	Methods for identifying adrenergic receptors
	MYOG:013-US
	 	6/19/1998	 	09/100,497	 	U.S.	 	5,998,458	 	12/7/1999	 	Positive inotrope + beta adrenergic receptor antagonist
	MYOG:013-WO
	 	6/24/1998	 	PCT/US98/13442	 	PCT	 	 	 	 	 	Positive inotrope + beta adrenergic receptor antagonist
	MYOG:013-AU
	 	1/6/2000	 	81740/98	 	Australia	 	731,656	 	7/19/2001	 	Positive inotrope + beta adrenergic receptor antagonist
	MYOG:013-CA
	 	12/23/1999	 	2,295,094	 	Canada	 	 	 	 	 	Positive inotrope + beta adrenergic receptor antagonist
	MYOG:013-EP
	 	1/25/2000	 	198,931,687	 	Europe	 	 	 	 	 	Positive inotrope + beta adrenergic receptor antagonist
	MYOG:013-JP
	 	12/27/1999	 	11-505056	 	Japan	 	 	 	 	 	Positive inotrope + beta adrenergic receptor antagonist
	MYOG:020-US
	 	10/15/1998	 	09/173,798	 	U.S.	 	6,201,165	 	3/13/2001	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	MYOG:020-WO
	 	10/16/1998	 	PCT/US98/21988	 	PCT	 	 	 	 	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	MYOG:020-AU
	 	4/16/2000	 	10992/99	 	Australia	 	755428	 	8/16/2002	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	MYOG:020-CA
	 	4/16/2000	 	2,315,244	 	Canada	 	 	 	 	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	MYOG:020-EP
	 	4/16/2000	 	98953672.7	 	Europe	 	 	 	 	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	MYOG:020-JP
	 	4/16/2000	 	2000-516026	 	Japan	 	 	 	 	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	MYOG:020-MX
	 	4/14/2000	 	0003678	 	Mexico	 	 	 	 	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	MYOG:023-US
	 	10/15/1998	 	09/173,795	 	U.S.	 	6,673,768	 	1/6/2004	 	Calcineurin Therapies
	MYOG:024-US
	 	11/10/1999	 	09/438,075	 	U.S.	 	6,372,957	 	4/16/2002	 	MEF2 methods of treatment
	MYOG:024-USC1
	 	1/9/2002	 	10/043,658	 	U.S.	 	 	 	 	 	MEF2 screening methods
	MYOG:024-WO
	 	11/10/1999	 	PCT/US99/26725	 	PCT	 	 	 	 	 	MEF2
	MYOG:024-CA
	 	5/7/2001	 	2,350,086	 	Canada	 	 	 	 	 	MEF2
	MYOG:024-EP
	 	5/21/2001	 	99971848.9	 	Europe	 	 	 	 	 	MEF2
	MYOG:024-JP
	 	5/10/2001	 	2000-581187	 	Japan	 	 	 	 	 	MEF2
	MYOG:025-US
	 	10/15/1998	 	09/173,799	 	U.S.	 	6,657,104	 	12/2/2003	 	Calcineurin transgenics
	MYOG:026-US
	 	8/20/2000	 	09/643,206	 	U.S.	 	6,632,628	 	8/20/2000	 	HDAC screening and treatment
	MYOG:026-USD1
	 	8/20/2003	 	10/637,403	 	U.S.	 	 	 	 	 	HDAC transgenics
	MYOG:026-WO
	 	8/20/2000	 	PCT/US00/22958	 	PCT	 	 	 	 	 	Class II HDACs
	MYOG:026-CA
	 	2/14/2002	 	2,382,045	 	Canada	 	 	 	 	 	Class II HDACs
	MYOG:026-EP
	 	3/13/2002	 	00955805.7	 	Europe	 	 	 	 	 	Class II HDACs
	MYOG:026-JP
	 	2/19/2002	 	2001-518892	 	Japan	 	 	 	 	 	Class II HDACs
	MYOG:028-US
	 	7/18/2001	 	09/908,988	 	U.S.	 	6,740,751	 	5/25/2004	 	Muscle Ring Finger Proteins (MURFS) Screening and Treatment
	MYOG:028-USD1
	 	2/10/2004	 	10/775,627	 	U.S.	 	7,005,512	 	2/28/2006	 	Muscle Ring Finger Proteins (MURFS) Screening and Treatment
	MYOG:028-USD2
	 	2/10/2004	 	10/775,649	 	U.S.	 	issue fee	 	paid	 	Muscle Ring Finger Proteins (MURFS)
	MYOG:029-US
	 	4/16/1998	 	09/061,417	 	U.S.	 	 	 	 	 	NF-AT3 inhibitors
	MYOG:029-WO
	 	10/16/1998	 	PCT/US98/21845	 	PCT	 	 	 	 	 	NF-AT3 inhibitors
	MYOG:029-AU
	 	10/15/1998	 	98058/98	 	Australia	 	748334	 	9/12/2002	 	NF-AT3 inhibitors
	MYOG:029-CA
	 	4/10/2000	 	2,306,448	 	Canada	 	 	 	 	 	NF-AT3 inhibitors
	MYOG:029-EP
	 	5/16/2000	 	9895233.7	 	Europe	 	 	 	 	 	NF-AT3 inhibitors
	MYOG:029-JP
	 	4/17/2000	 	2000-516024	 	Japan	 	 	 	 	 	NF-AT3 inhibitors
	MYOG:034-US
	 	9/26/2002	 	10/256,221	 	U.S.	 	6,707,686	 	3/16/2004	 	HDAC Inhibitors
	MYOG:034-USC1
	 	3/16/2004	 	10/801,985	 	U.S.	 	6,946,441	 	9/20/2005	 	Inhibiting HDACs

 

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Schedule 1.46 Myogen Patents
	PATENTS	 	Filing Date	 	App. No.	 	Country	 	Pat. No.	 	Issue Date	 	Subject Matter
	MYOG:034-USC2
	 	7/26/2005	 	11/190,074	 	U.S.	 	 	 	 	 	Inhibiting HDACs
	MYOG:034-USC3
	 	8/30/2005	 	11/215,844	 	U.S.	 	 	 	 	 	Inhibiting HDACs
	MYOG:034-EP
	 	9/27/2001	 	02/021678.8	 	Europe	 	1,297,851	 	1/26/2005	 	Inhibiting HDACs
	MYOG:034-EPD1
	 	1/25/2005	 	5001443	 	Europe	 	 	 	 	 	Inhibiting HDACs
	MYOG:034-JP
	 	9/27/2001	 	2002-284313	 	Japan	 	 	 	 	 	Inhibiting HDACs
	MYOG:035-US
	 	1/21/2003	 	10/348,598	 	U.S.	 	 	 	 	 	Hypertrophic Cell Line
	MYOG:036-US
	 	2/13/2001	 	09/782,953	 	U.S.	 	 	 	 	 	MCIP's screening, treatment, transgenics, antibodies
	MYOG:036-WO
	 	2/13/2001	 	PCT/US01/21662	 	PCT	 	 	 	 	 	MCIP's screening, treatment, transgenics, antibodies
	MYOG:036-CA
	 	1/24/2003	 	2,415,967	 	Canada	 	 	 	 	 	MCIP's screening, treatment, transgenics, antibodies
	MYOG:036-EP
	 	2/5/2003	 	1952568.2	 	Europe	 	 	 	 	 	MCIP's screening, treatment, transgenics, antibodies
	MYOG:036-JP
	 	12/26/2002	 	2002-509354	 	Japan	 	 	 	 	 	MCIP's screening, treatment, transgenics, antibodies
	MYOG:037-US
	 	8/20/2003	 	10/644,659	 	U.S.	 	 	 	 	 	STARS screening, treatment, transgenics, antibodies
	MYOG:044-US
	 	5/21/2003	 	10/848,820	 	U.S.	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:044-WO
	 	5/21/2003	 	PCT/US04/015715	 	PCT	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:044-AU
	 	5/21/2003	 	2004249114	 	Australia	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:044-BR
	 	5/21/2003	 	 	 	Brazil	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:044-CA
	 	5/21/2003	 	 	 	Canada	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:044-CN
	 	5/21/2003	 	 	 	China	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:044-EP
	 	5/21/2003	 	 	 	Europe	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:044-IN
	 	5/21/2003	 	 	 	India	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:044-JP
	 	5/21/2003	 	 	 	Japan	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:044-MX
	 	5/21/2003	 	 	 	Mexico	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:045-US
	 	11/3/2004	 	10/980,612	 	U.S.	 	 	 	 	 	Alpha myocin modulating compound 'R' enatiomer
	MYOG:045-WO
	 	11/3/2004	 	PCT/US04/036569	 	PCT	 	 	 	 	 	Alpha myocin modulating compound 'R' enatiomer
	MYOG:046-US
	 	11/3/2004	 	10/980,605	 	U.S.	 	 	 	 	 	Alpha myocin modulating compound 'S' enatiomer
	MYOG:046-US
	 	11/3/2004	 	PCT/US04/036568	 	PCT	 	 	 	 	 	Alpha myocin modulating compound 'S' enatiomer
	MYOG:047-US
	 	11/13/2004	 	10/988,192	 	U.S.	 	 	 	 	 	TRP Channel
	MYOG:047-WO
	 	11/13/2004	 	PCT/US04/037858	 	PCT	 	 	 	 	 	TRP Channel
	MYOG:048-US
	 	12/23/2004	 	11/018,426	 	U.S.	 	 	 	 	 	5-HT2 receptors
	MYOG:048-WO
	 	12/23/2004	 	PCT/US04/042922	 	PCT	 	 	 	 	 	5-HT2 receptors
	MYOG:049-US
	 	12/23/2004	 	11/018,383	 	U.S.	 	 	 	 	 	5-HT2 receptor binding compounds
	MYOG:049-WO
	 	12/23/2004	 	PCT/US04/042921	 	PCT	 	 	 	 	 	5-HT2 receptor binding compounds
	MYOG:050-US
	 	2/2/2005	 	11/049,630	 	U.S.	 	 	 	 	 	PRK (HDAC kinase II)
	MYOG:050-WO
	 	2/2/2005	 	PCT/US05/002808	 	PCT	 	 	 	 	 	PRK (HDAC kinase II)
	MYOG:054-US
	 	4/5/2005	 	11/099,417	 	U.S.	 	 	 	 	 	Nuclear export
	MYOG:054-WO
	 	4/5/2005	 	PCT/US05/011264	 	PCT	 	 	 	 	 	Nuclear export
	MYOG:057-WO
	 	9/19/2005	 	PCT/US05/033461	 	PCT	 	 	 	 	 	P38 MCIP
	MYOG:058-US
	 	8/15/2005	 	11/203,828	 	U.S.	 	 	 	 	 	Ku
	MYOG:060-USP1
	 	7/13/2005	 	60/699,189	 	U.S.	 	 	 	 	 	Proteasome inhibitors
	MYOG:062-USP1
	 	11/18/2005	 	60/737,952	 	U.S.	 	 	 	 	 	CAMKII/Calpain/HDACs
	UTSD:803-US
	 	5/30/2002	 	10/159,971	 	U.S.	 	6,924,415	 	8/2/2005	 	MEK5
	USTD:803-USD1
	 	4/21/2005	 	11/089,425	 	U.S.	 	 	 	 	 	MEK5
	UTSD:803-CA
	 	5/29/2002	 	2,384,907	 	Canada	 	 	 	 	 	MEK5
	UTSD:803-JP
	 	11/22/2001	 	2001-358595	 	Japan	 	 	 	 	 	MEK5
	USTD:1771-USP1
	 	5/3/2006	 	not yet assigned	 	U.S.	 	 	 	 	 	CAMTA

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]